<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006698</article-id><article-id pub-id-type="pmc">PMC11861857</article-id><article-id pub-id-type="doi">10.3390/vaccines13020151</article-id><article-id pub-id-type="publisher-id">vaccines-13-00151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Q Fever Vaccines: Unveiling the Historical Journey and Contemporary Innovations in Vaccine Development</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0000-2976-9460</contrib-id><name><surname>Christodoulou</surname><given-names>Magdalini</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6123-559X</contrib-id><name><surname>Papagiannis</surname><given-names>Dimitrios</given-names></name><xref rid="c1-vaccines-13-00151" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Leit&#x000e3;o</surname><given-names>Jorge H.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Lee</surname><given-names>John Hwa</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Senevirathne</surname><given-names>Amal</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00151">Public Health &#x00026; Adults Immunization Laboratory, Department of Nursing, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece; <email>magdachris@uth.gr</email></aff><author-notes><corresp id="c1-vaccines-13-00151"><label>*</label>Correspondence: <email>dpapajohn@uth.gr.com</email>; Tel.: +30-2410-684610</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>151</elocation-id><history><date date-type="received"><day>29</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>26</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Q fever is a zoonotic disease caused by the obligate intracellular bacterium <italic toggle="yes">Coxiella burnetii</italic> that presents significant challenges for global public health control. Current prevention relies primarily on the whole-cell vaccine &#x0201c;Q-VAX&#x0201d;, which despite its effectiveness, faces important limitations including pre-screening requirements and reactogenicity issues in previously sensitized individuals. This comprehensive review examines the complex interplay between pathogen characteristics, host immune responses, and vaccine development strategies. We analyze recent advances in understanding <italic toggle="yes">C. burnetii</italic>&#x02019;s molecular pathogenesis and host&#x02013;pathogen interactions that have informed vaccine design. The evolution of vaccine approaches is evaluated, from traditional whole-cell preparations to modern subunit, DNA, and multi-epitope designs. Particular attention is given to innovative technologies, including reverse vaccinology and immunoinformatics, that have enabled the identification of novel antigenic targets. Recent clinical data demonstrating the safety and immunogenicity of next-generation vaccine candidates are presented, alongside manufacturing and implementation considerations. While significant progress has been made in overcoming the limitations of first-generation vaccines, challenges remain in optimizing immunogenicity while ensuring safety across diverse populations. This review provides a critical analysis of current evidence and future directions in Q fever vaccine development, highlighting promising strategies for achieving more effective and broadly applicable vaccines.</p></abstract><kwd-group><kwd><italic toggle="yes">Coxiella burnetii</italic></kwd><kwd>Q fever vaccine</kwd><kwd>vaccine development</kwd><kwd>Q-VAX</kwd><kwd>reactogenicity</kwd><kwd>zoonotic disease</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00151"><title>1. Introduction</title><p>Q fever, a zoonotic disease caused by the obligate intracellular bacterium <italic toggle="yes">Coxiella burnetii</italic>, represents a significant global health challenge [<xref rid="B1-vaccines-13-00151" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00151" ref-type="bibr">2</xref>]. First documented in 1933 among Queensland abattoir workers [<xref rid="B3-vaccines-13-00151" ref-type="bibr">3</xref>], the disease was termed &#x0201c;Q fever&#x0201d; (Query fever) due to its initially unknown etiology. Early research by Burnet and Freeman established fundamental principles of disease pathogenesis [<xref rid="B4-vaccines-13-00151" ref-type="bibr">4</xref>], culminating in Burnet&#x02019;s identification of the causative rickettsia-like organism in 1937 [<xref rid="B5-vaccines-13-00151" ref-type="bibr">5</xref>]. Cox and Davis&#x02019;s subsequent isolation of <italic toggle="yes">C. burnetii</italic> from ticks in 1938 confirmed its vector-borne transmission capabilities [<xref rid="B6-vaccines-13-00151" ref-type="bibr">6</xref>], leading to its establishment as a distinct genus in 1948 [<xref rid="B5-vaccines-13-00151" ref-type="bibr">5</xref>,<xref rid="B7-vaccines-13-00151" ref-type="bibr">7</xref>]. The pathogen exhibits remarkable characteristics that pose unique challenges for disease control [<xref rid="B8-vaccines-13-00151" ref-type="bibr">8</xref>]. Its exceptional ability to survive in diverse environments, coupled with efficient airborne transmission [<xref rid="B9-vaccines-13-00151" ref-type="bibr">9</xref>] and minimal infectious dose [<xref rid="B10-vaccines-13-00151" ref-type="bibr">10</xref>], creates substantial risks, particularly among veterinarians, farmers, and abattoir workers [<xref rid="B11-vaccines-13-00151" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00151" ref-type="bibr">12</xref>]. <italic toggle="yes">C. burnetii</italic>&#x02019;s sophisticated intracellular survival mechanisms and immune evasion strategies add considerable complexity to disease management [<xref rid="B13-vaccines-13-00151" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00151" ref-type="bibr">14</xref>]. Building on these foundational discoveries, the research focus has shifted toward understanding molecular mechanisms and developing preventive strategies [<xref rid="B15-vaccines-13-00151" ref-type="bibr">15</xref>].</p><p>The completion of <italic toggle="yes">C. burnetii</italic> genome sequencing in 2003 marked a pivotal advancement, revealing genes involved in immune evasion and host adaptation [<xref rid="B16-vaccines-13-00151" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-13-00151" ref-type="bibr">17</xref>]. This breakthrough enabled sophisticated experimental approaches [<xref rid="B18-vaccines-13-00151" ref-type="bibr">18</xref>], including proteomic profiling and microarray analysis, facilitating the identification of potential vaccine targets [<xref rid="B19-vaccines-13-00151" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-13-00151" ref-type="bibr">20</xref>]. The development of axenic media in 2009 addressed long-standing cultivation challenges, enabling genetic manipulation studies and functional analyses of virulence factors [<xref rid="B21-vaccines-13-00151" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00151" ref-type="bibr">22</xref>]. The significance of effective prevention strategies became particularly evident during the Netherlands outbreak (2007&#x02013;2010), the largest documented epidemic with over 4000 human cases linked to infected dairy goats [<xref rid="B23-vaccines-13-00151" ref-type="bibr">23</xref>]. This event necessitated comprehensive control measures, including mandatory livestock vaccination and enhanced surveillance protocols [<xref rid="B24-vaccines-13-00151" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-13-00151" ref-type="bibr">25</xref>]. The outbreak highlighted the critical importance of integrating veterinary and public health approaches in disease control. Vaccine development has faced significant challenges due to <italic toggle="yes">C. burnetii</italic>&#x02019;s intracellular nature, requiring a careful balance between immunogenicity and safety [<xref rid="B26-vaccines-13-00151" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-13-00151" ref-type="bibr">27</xref>]. Successful immunity demands coordination of both humoral immunity for bacterial neutralization and cell-mediated responses to eliminate intracellular pathogens [<xref rid="B28-vaccines-13-00151" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-13-00151" ref-type="bibr">29</xref>]. The licensing of Q-VAX, Q Fever Vaccine (AUST R 100517) in Australia (1989) marked a significant milestone [<xref rid="B30-vaccines-13-00151" ref-type="bibr">30</xref>], demonstrating strong efficacy in high-risk populations [<xref rid="B31-vaccines-13-00151" ref-type="bibr">31</xref>].</p><p>However, reactogenicity in pre-sensitized individuals necessitated screening protocols, limiting global implementation [<xref rid="B32-vaccines-13-00151" ref-type="bibr">32</xref>]. Recent advances in genomic and immunologic technologies have enabled the development of innovative vaccine approaches. These include subunit vaccines targeting specific bacterial antigens, DNA-based platforms, and multi-epitope designs integrating multiple antigenic determinants [<xref rid="B19-vaccines-13-00151" ref-type="bibr">19</xref>,<xref rid="B33-vaccines-13-00151" ref-type="bibr">33</xref>]. By 2017, researchers had developed platforms specifically addressing reactogenicity through targeted antigen selection [<xref rid="B29-vaccines-13-00151" ref-type="bibr">29</xref>,<xref rid="B34-vaccines-13-00151" ref-type="bibr">34</xref>], while subsequent work focused on optimizing formulations and adjuvants [<xref rid="B35-vaccines-13-00151" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-13-00151" ref-type="bibr">36</xref>]. This comprehensive review examines the evolution of Q fever vaccine development through an analysis of pathogen characteristics, host immune responses, and emerging technologies [<xref rid="B37-vaccines-13-00151" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-13-00151" ref-type="bibr">38</xref>]. Our examination provides insights into rational design strategies for next-generation vaccines, addressing the continuing challenge of achieving widespread immunity while maintaining safety and efficacy. Summarizing the milestones <xref rid="vaccines-13-00151-f001" ref-type="fig">Figure 1</xref> gives a timeline of the history of Q fever research and vaccine development, highlighting scientific discoveries, technological advances, and public health interventions.</p></sec><sec id="sec2-vaccines-13-00151"><title>2. Biology of <italic toggle="yes">Coxiella burnetii</italic></title><p><italic toggle="yes">Coxiella burnetii</italic>, the etiological agent of Q fever, is an obligate intracellular pathogen that exhibits remarkable adaptability to diverse environments and host cells [<xref rid="B14-vaccines-13-00151" ref-type="bibr">14</xref>]. This small, Gram-negative bacterium belongs to the order Legionellales within <italic toggle="yes">the Gammaproteobacteria</italic> class and is closely related to <italic toggle="yes">Legionella pneumophila</italic> [<xref rid="B39-vaccines-13-00151" ref-type="bibr">39</xref>]. The organism demonstrates highly successful adaptation to intracellular growth, requiring specific conditions including an acidic pH (~4.75) for optimal replication within host cells [<xref rid="B40-vaccines-13-00151" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00151" ref-type="bibr">41</xref>]. <italic toggle="yes">Coxiella burnetii</italic>, belonging to the order Legionellales and the family Coxiel-laceae, is a small obligate intracellular gram-negative bacterium that causes Q-fever in humans and coxiellosis in wild and domestic animals <xref rid="vaccines-13-00151-f002" ref-type="fig">Figure 2</xref>.</p><p><italic toggle="yes">C. burnetii</italic>&#x02019;s unique biological features, including a biphasic developmental cycle, a specialized cell envelope, and a sophisticated Type IV secretion system (T4SS), enable it to survive in harsh environmental conditions and efficiently infect a wide range of hosts [<xref rid="B42-vaccines-13-00151" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00151" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00151" ref-type="bibr">44</xref>]. The bacterium&#x02019;s low infectious dose (ID50: 1-10 bacteria) and high environmental stability contribute to its classification as a potential bioterrorist agent [<xref rid="B45-vaccines-13-00151" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00151" ref-type="bibr">46</xref>].</p><p><italic toggle="yes">C. burnetii</italic> undergoes a biphasic developmental cycle, transitioning between two morphologically and physiologically distinct forms: the environmentally stable small cell variant (SCV) and the metabolically active large cell variant (LCV). SCVs enter alveolar macrophages through phagocytosis and proceed through the endocytic pathway. Upon fusion of the pathogen-containing phagosome with lysosomes, the SCVs convert to LCVs, and the Dot/Icm secretion system (SS) is activated. Through the activity of effector proteins, the mature phagolysosome is converted into the replication-permissive Coxiella containing vacuole (CCV). The CCV rapidly expands through heterotypic fusion with autophagosomes, lysosomes, and endocytic vesicles and homotypic fusion of multiple CCVs. As the CCV expands and fills with bacteria, the LCVs convert back to SCVs, where they will be stable upon release from the cell via cell lysis or exocytosis) [<xref rid="B47-vaccines-13-00151" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00151" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00151" ref-type="bibr">49</xref>]. The SCV, a compact, rod-shaped form (0.2&#x02013;0.4 &#x003bc;m wide, 0.4&#x02013;1.0 &#x003bc;m long), is adapted for extracellular survival [<xref rid="B50-vaccines-13-00151" ref-type="bibr">50</xref>]. Its condensed chromatin and highly cross-linked peptidoglycan layer confer resistance to stressors such as extreme temperature, pressure, UV light, and desiccation [<xref rid="B50-vaccines-13-00151" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-13-00151" ref-type="bibr">51</xref>]. The peptidoglycan of SCVs exhibits a unique composition, with a high proportion of 3-3 cross-links maintained by DD transpeptidases (CBU_0545) and LD transpeptidases (CBU_0823) [<xref rid="B49-vaccines-13-00151" ref-type="bibr">49</xref>]. In contrast, the LCV is larger in size (up to 2 &#x003bc;m long), more pleomorphic, and metabolically active, serving as the replicative form within host cells [<xref rid="B52-vaccines-13-00151" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-13-00151" ref-type="bibr">53</xref>]. Transition from SCV to LCV occurs in the acidic environment (pH ~4.75) of the Coxiella-containing vacuole (CCV) and is accompanied by global changes in gene expression and metabolism [<xref rid="B43-vaccines-13-00151" ref-type="bibr">43</xref>]. These changes are regulated by key transcription factors, such as RpoS (CBU_1669) and the two-component system PmrAB [<xref rid="B54-vaccines-13-00151" ref-type="bibr">54</xref>]. During the intracellular growth phase, LCVs replicate with a doubling time of approximately 10&#x02013;12 h, before differentiating back into SCVs at the late stages of infection [<xref rid="B48-vaccines-13-00151" ref-type="bibr">48</xref>,<xref rid="B55-vaccines-13-00151" ref-type="bibr">55</xref>]. <italic toggle="yes">C. burnetii</italic>&#x02019;s cell envelope plays a crucial role in host&#x02013;pathogen interactions and immune evasion. The outer membrane contains a unique lipopolysaccharide (LPS) that undergoes phase variation [<xref rid="B56-vaccines-13-00151" ref-type="bibr">56</xref>]. Virulent phase I bacteria produce a full-length LPS with O-antigen containing virenose and dihydrohydroxystreptose, while avirulent phase II bacteria express a truncated LPS lacking the Oantigen [<xref rid="B57-vaccines-13-00151" ref-type="bibr">57</xref>]. The phase I LPS is critical for evading host immune responses, as it masks surface antigens and confers resistance to complement-mediated killing [<xref rid="B56-vaccines-13-00151" ref-type="bibr">56</xref>,<xref rid="B58-vaccines-13-00151" ref-type="bibr">58</xref>]. Conversely, phase II LPS is more readily recognized by pattern recognition receptors (PRRs), eliciting a robust inflammatory response [<xref rid="B59-vaccines-13-00151" ref-type="bibr">59</xref>]. The LPS of <italic toggle="yes">C. burnetii</italic> features an unconventional structure, with rare sugar residues such as virenose and dihydrohydroxystreptose in the Oantigen, and mannose and D-glycero-D-manno-heptose in the core oligosaccharide [<xref rid="B51-vaccines-13-00151" ref-type="bibr">51</xref>,<xref rid="B57-vaccines-13-00151" ref-type="bibr">57</xref>]. The lipid A moiety exhibits atypical acylation patterns that diverge from classical enterobacterial lipid A, contributing to reduced endotoxicity [<xref rid="B57-vaccines-13-00151" ref-type="bibr">57</xref>,<xref rid="B60-vaccines-13-00151" ref-type="bibr">60</xref>]. Important components of the cell envelope include the porin P1 (CBU_0311), which facilitates nutrient uptake [<xref rid="B61-vaccines-13-00151" ref-type="bibr">61</xref>], and the outer membrane protein Com1 (CBU_1910), which is involved in host cell interactions [<xref rid="B62-vaccines-13-00151" ref-type="bibr">62</xref>]. A hallmark of <italic toggle="yes">C. burnetii</italic> pathogenesis is the Dot/Icm (Defective in Organelle Trafficking/Intracellular Multiplication) T4SS, which translocates bacterial effector proteins into the host cell cytosol [<xref rid="B42-vaccines-13-00151" ref-type="bibr">42</xref>,<xref rid="B63-vaccines-13-00151" ref-type="bibr">63</xref>]. The Dot/Icm system is homologous to that of Legionella pneumophila and is encoded by 23 genes scattered throughout the <italic toggle="yes">C. burnetii</italic> genome [<xref rid="B63-vaccines-13-00151" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-13-00151" ref-type="bibr">64</xref>]. CirA (CBU0041), along with other T4SS components, plays crucial roles in bacterial virulence and intracellular survival [<xref rid="B65-vaccines-13-00151" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-13-00151" ref-type="bibr">66</xref>].</p><p><italic toggle="yes">Coxiella burnetii</italic>, is an obligate intracellular pathogen that exhibits remarkable adaptability to diverse environments and host cells <xref rid="vaccines-13-00151-f003" ref-type="fig">Figure 3</xref>.</p><p>Over 130 <italic toggle="yes">C. burnetii</italic> T4SS substrates have been identified through genetic and bioinformatic screens, highlighting the diverse repertoire of effectors employed by this pathogen [<xref rid="B67-vaccines-13-00151" ref-type="bibr">67</xref>]. These effectors manipulate multiple host cell pathways, including apoptosis, autophagy, vesicular trafficking, and innate immune signaling. For example, the effector AnkG interferes with the host apoptotic machinery by interacting with the pro-apoptotic protein p32, thereby promoting host cell survival [<xref rid="B68-vaccines-13-00151" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-13-00151" ref-type="bibr">69</xref>]. Other notable effectors include CvpA, which subverts clathrin-mediated vesicular transport [<xref rid="B70-vaccines-13-00151" ref-type="bibr">70</xref>], CvpB/Cig2, which promotes autophagosome formation and fusion with the CCV [<xref rid="B71-vaccines-13-00151" ref-type="bibr">71</xref>], and NopA (CBU1217), which modulates the nuclear translocation of NF-&#x003ba;B [<xref rid="B72-vaccines-13-00151" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-13-00151" ref-type="bibr">73</xref>].Comparative genomic analyses have revealed substantial plasticity in the effector repertoires among different <italic toggle="yes">C. burnetii</italic> strains [<xref rid="B74-vaccines-13-00151" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-13-00151" ref-type="bibr">75</xref>]. A subset of effectors, including AnkG, CaeA, and CvpB, is conserved across all sequenced isolates, suggesting their essential roles in intracellular parasitism [<xref rid="B75-vaccines-13-00151" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-13-00151" ref-type="bibr">76</xref>]. In contrast, many effectors exhibit polymorphisms or are entirely absent in certain strains, potentially contributing to differences in virulence and host tropism [<xref rid="B70-vaccines-13-00151" ref-type="bibr">70</xref>,<xref rid="B76-vaccines-13-00151" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-13-00151" ref-type="bibr">77</xref>]. <italic toggle="yes">C. burnetii</italic> has evolved a complex metabolic network tailored to the intracellular lifestyle. The organism&#x02019;s adaptation to acidic pH (~4.75) is particularly noteworthy, as it represents a unique metabolic optimization for growth within the lysosome-derived CCV [<xref rid="B75-vaccines-13-00151" ref-type="bibr">75</xref>,<xref rid="B78-vaccines-13-00151" ref-type="bibr">78</xref>] Within the acidic CCV, <italic toggle="yes">C. burnetii</italic> upregulates key metabolic pathways, including the TCA cycle, glycolysis/gluconeogenesis, and fatty acid &#x003b2;-oxidation, to support replication [<xref rid="B79-vaccines-13-00151" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-13-00151" ref-type="bibr">80</xref>]. A pivotal regulator of <italic toggle="yes">C. burnetii</italic> metabolism is the PmrAB two-component system, which senses environmental cues such as low pH and cationic peptides [<xref rid="B75-vaccines-13-00151" ref-type="bibr">75</xref>,<xref rid="B78-vaccines-13-00151" ref-type="bibr">78</xref>]. This sophisticated sensing mechanism allows the bacterium to rapidly adapt its metabolic and virulence programs in response to environmental conditions. The PmrAB system controls the expression of genes involved in LPS modification, oxidative stress response, and metabolic adaptation, facilitating the bacterium&#x02019;s survival within the harsh vacuolar compartment [<xref rid="B75-vaccines-13-00151" ref-type="bibr">75</xref>,<xref rid="B78-vaccines-13-00151" ref-type="bibr">78</xref>]. Upon inhalation by a mammalian host, <italic toggle="yes">C. burnetii</italic> SCVs are phagocytosed by alveolar macrophages, the primary target cells for infection. The bacterium&#x02019;s ability to survive and replicate within professional phagocytes demonstrates its remarkable adaptation to intracellular life [<xref rid="B81-vaccines-13-00151" ref-type="bibr">81</xref>]. The nascent phagosome containing <italic toggle="yes">C. burnetii</italic> undergoes a maturation process, sequentially fusing with early endosomes, late endosomes, and lysosomes [<xref rid="B82-vaccines-13-00151" ref-type="bibr">82</xref>]. This maturation is accompanied by a progressive acidification of the phagosomal lumen and the acquisition of various markers, such as Rab5, Rab7, LAMP1, and cathepsins [<xref rid="B13-vaccines-13-00151" ref-type="bibr">13</xref>,<xref rid="B83-vaccines-13-00151" ref-type="bibr">83</xref>,<xref rid="B84-vaccines-13-00151" ref-type="bibr">84</xref>]. Unlike other intracellular pathogens, <italic toggle="yes">Coxiella burnetii</italic> facilitates the formation of the Coxiella-containing vacuole (CCV), a lysosome-derived compartment with an acidic pH (~4.75) and hydrolytic activity. This vacuole provides a protective niche for replication and expands significantly during infection, eventually dominating the host cell cytoplasm [<xref rid="B14-vaccines-13-00151" ref-type="bibr">14</xref>,<xref rid="B85-vaccines-13-00151" ref-type="bibr">85</xref>]. The formation and maintenance of the CCV involve a coordinated interplay between <italic toggle="yes">Coxiella burnetii</italic> effectors and host cell factors. The bacterium&#x02019;s T4SS effectors, including CvpA [<xref rid="B70-vaccines-13-00151" ref-type="bibr">70</xref>], CvpB [<xref rid="B71-vaccines-13-00151" ref-type="bibr">71</xref>], and Cig57 [<xref rid="B86-vaccines-13-00151" ref-type="bibr">86</xref>], manipulate host vesicular trafficking to promote fusion of the CCV with autophagosomes, endosomes, and ER-derived vesicles [<xref rid="B87-vaccines-13-00151" ref-type="bibr">87</xref>]. These processes supply membranes for CCV expansion and deliver nutrients essential for bacterial growth. Host GTPases, including Rab1b, Rab5, and Rab7, are actively recruited to the CCV membrane and play essential roles in vacuole maturation and maintenance [<xref rid="B88-vaccines-13-00151" ref-type="bibr">88</xref>,<xref rid="B89-vaccines-13-00151" ref-type="bibr">89</xref>]. The bacterium&#x02019;s ability to manipulate these host cell factors highlights its sophisticated control over cellular processes. The recruitment of these GTPases is mediated by specific bacterial effectors, such as CvpB, which interacts with phosphoinositide&#x02019;s and inhibits the activity of the lipid kinase PIKfyve, leading to an accumulation of PI(3)P on the CCV membrane [<xref rid="B71-vaccines-13-00151" ref-type="bibr">71</xref>,<xref rid="B90-vaccines-13-00151" ref-type="bibr">90</xref>]. As the CCV matures, <italic toggle="yes">C. burnetii</italic> enters an exponential growth phase, replicating with a doubling time of approximately 10&#x02013;12 h [<xref rid="B69-vaccines-13-00151" ref-type="bibr">69</xref>]. The replicating bacteria evade host cell defenses and maintain CCV integrity through multiple effector-mediated strategies. For example, the effectors CaeA and AnkG (CBU0781) inhibit apoptosis by targeting pro-apoptotic proteins, while other effectors localize to the nucleus and modulate host gene expression [<xref rid="B91-vaccines-13-00151" ref-type="bibr">91</xref>]. In the late stages of infection (&#x0003e;6 days), the CCV occupies the majority of the host cell cytoplasm, and the bacteria begin to transition back to the SCV form [<xref rid="B49-vaccines-13-00151" ref-type="bibr">49</xref>,<xref rid="B91-vaccines-13-00151" ref-type="bibr">91</xref>]. This process involves a global downregulation of metabolic genes and the induction of stress response pathways, such as the oxidative stress response regulated by specific effectors [<xref rid="B92-vaccines-13-00151" ref-type="bibr">92</xref>]. Eventually, the host cell lyses, releasing a mixture of SCVs and LCVs into the extracellular environment, where the SCVs can persist and maintain infectivity for extended periods [<xref rid="B91-vaccines-13-00151" ref-type="bibr">91</xref>]. Another important aspect of <italic toggle="yes">C. burnetii</italic>&#x02019;s intracellular survival strategy is the subversion of autophagy. Although initially thought to function as a host defense mechanism, autophagy is actively exploited by <italic toggle="yes">C. burnetii</italic> to promote CCV expansion and bacterial replication [<xref rid="B93-vaccines-13-00151" ref-type="bibr">93</xref>]. The effector CvpB/Cig2 stimulates the formation of autophagosomes and facilitates their fusion with the CCV, providing a membrane for vacuole growth [<xref rid="B71-vaccines-13-00151" ref-type="bibr">71</xref>]. CpeB promotes LC3-II accumulation and contributes to bacterial virulence [<xref rid="B94-vaccines-13-00151" ref-type="bibr">94</xref>], while CvpF interacts with RAB26 to recruit LC3B to CCVs [<xref rid="B95-vaccines-13-00151" ref-type="bibr">95</xref>]. Understanding the complex interplay between <italic toggle="yes">C. burnetii</italic> and its host provides valuable insights into the development of effective preventive and therapeutic strategies against Q fever.</p></sec><sec id="sec3-vaccines-13-00151"><title>3. Host Immune Response to <italic toggle="yes">C. burnetii</italic> Infection</title><p>The host immune response to <italic toggle="yes">Coxiella burnetii</italic> involves a complex interplay between innate and adaptive immunity, which shapes the immediate defense mechanisms and long-term protection against the pathogen [<xref rid="B26-vaccines-13-00151" ref-type="bibr">26</xref>,<xref rid="B96-vaccines-13-00151" ref-type="bibr">96</xref>]. The initial recognition of <italic toggle="yes">C. burnetii</italic> occurs through pattern recognition receptors (PRRs), particularly Toll-like receptor 2 (TLR2) and TLR4, which detect bacterial components such as lipopolysaccharide (LPS) and other pathogen-associated molecular patterns (PAMPs) [<xref rid="B59-vaccines-13-00151" ref-type="bibr">59</xref>,<xref rid="B97-vaccines-13-00151" ref-type="bibr">97</xref>]. This recognition triggers crucial signaling cascades that activate innate immune cells and stimulate the production of pro-inflammatory cytokines [<xref rid="B98-vaccines-13-00151" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-13-00151" ref-type="bibr">99</xref>]. During the early stages of infection, alveolar macrophages and dendritic cells play a pivotal role in pathogen recognition and the secretion of key cytokines, including interleukin-1&#x003b2; (IL-1&#x003b2;), tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), and IL-6 [<xref rid="B99-vaccines-13-00151" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-13-00151" ref-type="bibr">100</xref>]. These inflammatory mediators orchestrate the recruitment of additional immune cells to the sites of infection [<xref rid="B101-vaccines-13-00151" ref-type="bibr">101</xref>]. Natural killer (NK) cells also contribute significantly to early defense through the production of interferon-&#x003b3; (IFN-&#x003b3;) and their cytotoxic activity against infected cells [<xref rid="B102-vaccines-13-00151" ref-type="bibr">102</xref>]. Although the complement system is activated during <italic toggle="yes">C. burnetii</italic> infection, Phase I organisms exhibit notable resistance to complement-mediated killing due to their unique LPS structure [<xref rid="B85-vaccines-13-00151" ref-type="bibr">85</xref>,<xref rid="B103-vaccines-13-00151" ref-type="bibr">103</xref>]. The adaptive immune response to <italic toggle="yes">C. burnetii</italic> develops over several weeks post-infection and involves both cellular and humoral components [<xref rid="B58-vaccines-13-00151" ref-type="bibr">58</xref>]. CD4+ T helper cells, particularly those exhibiting a T helper 1 (Th1) phenotype, play a central role in orchestrating the adaptive response through the production of IFN-&#x003b3; and other cytokines that enhance the bactericidal activity of macrophages [<xref rid="B104-vaccines-13-00151" ref-type="bibr">104</xref>]. This cell-mediated immunity is crucial for controlling intracellular infection and establishing long-term protection against <italic toggle="yes">C. burnetii</italic> [<xref rid="B29-vaccines-13-00151" ref-type="bibr">29</xref>,<xref rid="B105-vaccines-13-00151" ref-type="bibr">105</xref>]. CD8+ cytotoxic T lymphocytes (CTLs) also contribute to the host defense by recognizing and eliminating infected cells [<xref rid="B106-vaccines-13-00151" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-13-00151" ref-type="bibr">107</xref>]. The development of antigen-specific T cells provides the foundation for long-term immunity against <italic toggle="yes">C. burnetii</italic> infection [<xref rid="B65-vaccines-13-00151" ref-type="bibr">65</xref>]. These cells persist as memory T cells, enabling rapid responses upon subsequent exposure to the pathogen [<xref rid="B104-vaccines-13-00151" ref-type="bibr">104</xref>]. Humoral immunity develops through the production of specific antibodies against Phase I and Phase II antigens of <italic toggle="yes">C. burnetii</italic> [<xref rid="B18-vaccines-13-00151" ref-type="bibr">18</xref>,<xref rid="B26-vaccines-13-00151" ref-type="bibr">26</xref>]. IgG antibodies predominate the humoral response, with different subclasses showing varying degrees of effectiveness in bacterial neutralization [<xref rid="B108-vaccines-13-00151" ref-type="bibr">108</xref>]. Phase I antibodies, which appear later in the course of infection, correlate strongly with protective immunity, while Phase II antibodies emerge earlier but provide less protection [<xref rid="B109-vaccines-13-00151" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-13-00151" ref-type="bibr">110</xref>]. The timing and magnitude of these antibody responses often serve as important diagnostic indicators of disease progression and treatment efficacy [<xref rid="B111-vaccines-13-00151" ref-type="bibr">111</xref>]. The establishment of immunological memory involves both T- and B-cell components [<xref rid="B46-vaccines-13-00151" ref-type="bibr">46</xref>]. Memory B cells and long-lived plasma cells maintain protective antibody levels, while memory T cells provide rapid recall responses upon re-exposure to the pathogen [<xref rid="B112-vaccines-13-00151" ref-type="bibr">112</xref>]. This dual-component memory system forms the basis for vaccine-induced protection and natural immunity against reinfection [<xref rid="B113-vaccines-13-00151" ref-type="bibr">113</xref>]. The duration and quality of this immunity significantly influence an individual&#x02019;s susceptibility to reinfection and the efficacy of vaccination [<xref rid="B26-vaccines-13-00151" ref-type="bibr">26</xref>]. Chronic <italic toggle="yes">C. burnetii</italic> infection often reflects a complex immunological dysfunction in which, despite robust immune responses, the host fails to eliminate the pathogen [<xref rid="B114-vaccines-13-00151" ref-type="bibr">114</xref>]. This persistence may result from bacterial immune evasion mechanisms, host genetic factors, or a combination of both [<xref rid="B115-vaccines-13-00151" ref-type="bibr">115</xref>]. Understanding these immune response patterns has crucial implications for vaccine development and therapeutic strategies, particularly in preventing chronic infection in high-risk individuals [<xref rid="B115-vaccines-13-00151" ref-type="bibr">115</xref>].</p></sec><sec id="sec4-vaccines-13-00151"><title>4. Pathogenesis of Q Fever</title><p>Q fever pathogenesis reflects complex interactions between <italic toggle="yes">C. burnetii</italic> and host immune responses, manifesting in acute and chronic forms with distinct clinical presentations [<xref rid="B116-vaccines-13-00151" ref-type="bibr">116</xref>]. Initial infection typically occurs through inhalation of contaminated aerosols, with the bacterium demonstrating remarkable infectivity at low doses [<xref rid="B117-vaccines-13-00151" ref-type="bibr">117</xref>]. Upon entering the respiratory tract, <italic toggle="yes">C. burnetii</italic> primarily targets alveolar macrophages, establishing initial infection through receptor-mediated phagocytosis [<xref rid="B118-vaccines-13-00151" ref-type="bibr">118</xref>]. Following initial infection, <italic toggle="yes">C. burnetii</italic> disseminates through lymphatic and blood circulation, establishing secondary infection sites in various organs, particularly the lungs, liver, and spleen. The bacterium&#x02019;s unique ability to survive and replicate within acidified parasitophorous vacuoles enables persistent infection despite host immune responses [<xref rid="B119-vaccines-13-00151" ref-type="bibr">119</xref>]. This adaptive mechanism proves crucial for both acute and chronic disease manifestations. Acute Q fever develops after an incubation period of 2&#x02013;3 weeks [<xref rid="B116-vaccines-13-00151" ref-type="bibr">116</xref>], characterized by the formation of distinctive granulomas comprising epithelioid cells and macrophages surrounding central lipid vacuoles [<xref rid="B120-vaccines-13-00151" ref-type="bibr">120</xref>,<xref rid="B121-vaccines-13-00151" ref-type="bibr">121</xref>]. These &#x0201c;doughnut granulomas&#x0201d; represent the host&#x02019;s attempt to contain infection and appear prominently in liver tissue [<xref rid="B122-vaccines-13-00151" ref-type="bibr">122</xref>]. Clinical manifestations vary significantly, ranging from asymptomatic infection to severe pneumonia or hepatitis [<xref rid="B123-vaccines-13-00151" ref-type="bibr">123</xref>], reflecting differences in host immune responses and initial bacterial burden [<xref rid="B124-vaccines-13-00151" ref-type="bibr">124</xref>]. The development of chronic Q fever involves persistent bacterial replication within target tissues [<xref rid="B125-vaccines-13-00151" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-13-00151" ref-type="bibr">126</xref>]. It particularly affects individuals with predisposing conditions such as valvular heart disease, vascular abnormalities, or immunosuppression [<xref rid="B25-vaccines-13-00151" ref-type="bibr">25</xref>]. Endocarditis represents the most severe manifestation, characterized by continuous bacterial proliferation within cardiac vegetations [<xref rid="B127-vaccines-13-00151" ref-type="bibr">127</xref>]. Pathological features include inflammation, fibrosis, and valve calcification, with ongoing immune responses contributing to tissue damage while failing to eliminate the pathogen [<xref rid="B128-vaccines-13-00151" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-13-00151" ref-type="bibr">129</xref>]. Vascular infections in chronic Q fever demonstrate similar pathogenic mechanisms, with bacterial persistence in vessel walls leading to inflammation, aneurysm formation, and potential rupture [<xref rid="B130-vaccines-13-00151" ref-type="bibr">130</xref>]. The ability of <italic toggle="yes">C. burnetii</italic> to maintain chronic infection despite apparent immune responses reflects sophisticated evasion strategies and adaptation to the intracellular niche [<xref rid="B131-vaccines-13-00151" ref-type="bibr">131</xref>]. Persistent infection triggers continuous immune activation, resulting in tissue damage through both direct bacterial effects and immunopathological mechanisms [<xref rid="B132-vaccines-13-00151" ref-type="bibr">132</xref>].</p><p>Q fever pathogenesis in acute and chronic forms. A small percentage of people fewer than 2&#x02013;5% who become infected with <italic toggle="yes">Coxiella burnetii</italic> bacteria develop a more serious infection called chronic Q fever. Chronic Q fever develops months or years following initial Q fever infection. People with chronic Q fever can develop an infection of their heart valves (endocarditis). People with endocarditis may experience night sweats, fatigue, shortness of breath, weight loss, or swelling of their limbs <xref rid="vaccines-13-00151-f004" ref-type="fig">Figure 4</xref>.</p><p>Immunopathological aspects of Q fever involve both protective and destructive immune responses [<xref rid="B97-vaccines-13-00151" ref-type="bibr">97</xref>]. Rapid cell-mediated immunity development in acute infection typically leads to bacterial clearance but may cause collateral tissue damage through excessive inflammation [<xref rid="B96-vaccines-13-00151" ref-type="bibr">96</xref>]. Chronic infections demonstrate persistent antigenic stimulation, resulting in ongoing inflammation and contributing to progressive tissue damage while failing to eliminate pathogens [<xref rid="B133-vaccines-13-00151" ref-type="bibr">133</xref>]. The disease exhibits notable organ tropism, with specific manifestations varying between acute and chronic forms [<xref rid="B134-vaccines-13-00151" ref-type="bibr">134</xref>]. Acute infection predominantly affects the lungs, liver, and spleen, while chronic infection shows a predilection for cardiovascular tissues [<xref rid="B135-vaccines-13-00151" ref-type="bibr">135</xref>]. This tissue specificity likely reflects bacterial adaptations and local host factors influencing infection susceptibility and immune response effectiveness [<xref rid="B136-vaccines-13-00151" ref-type="bibr">136</xref>]. The transition from acute to chronic infection is critical to the Q fever pathogenesis, influenced by the host immune status, genetic factors, and bacterial virulence determinants [<xref rid="B137-vaccines-13-00151" ref-type="bibr">137</xref>]. Understanding this transition&#x02019;s mechanisms proves crucial for identifying high-risk individuals and developing targeted therapeutic strategies [<xref rid="B138-vaccines-13-00151" ref-type="bibr">138</xref>]. Recent research has highlighted the role of host genetic polymorphisms in susceptibility to chronic infection, suggesting potential markers for risk stratification [<xref rid="B139-vaccines-13-00151" ref-type="bibr">139</xref>].</p></sec><sec id="sec5-vaccines-13-00151"><title>5. Modern Innovations in Q Fever Vaccine Development</title><p>In recent years, significant progress has been made in the development of next-generation Q fever vaccines that aim to address the shortcomings of traditional whole-cell formulations. These innovative approaches utilize state-of-the-art technologies and a comprehensive understanding of <italic toggle="yes">Coxiella burnetii</italic> immunology to engineer safer and more efficacious vaccine candidates [<xref rid="B76-vaccines-13-00151" ref-type="bibr">76</xref>].</p><p>One promising strategy is the development of subunit vaccines containing specific immunogenic <italic toggle="yes">C. burnetii</italic> antigens. Bioinformatic tools, such as reverse vaccinology, have facilitated the identification of potential vaccine targets based on genomic and proteomic data. Several studies have assessed predicted antigens and epitopes in animal models, with some demonstrating the capability to elicit protective cell-mediated immunity. For instance, HLA class II epitopes identified through immunoinformatic analysis were able to induce robust IFN-&#x003b3; recall responses in HLA-DR3 transgenic mice and individuals exposed to Q fever [<xref rid="B140-vaccines-13-00151" ref-type="bibr">140</xref>]. Moreover, immunization with a cocktail of MHC class II epitopes conferred protection in mice, emphasizing the significance of T-cell responses [<xref rid="B34-vaccines-13-00151" ref-type="bibr">34</xref>]. In addition to proteins, the <italic toggle="yes">C. burnetii</italic> phase I lipopolysaccharide (LPS) has emerged as a critical vaccine antigen. LPS-based candidates, such as chloroform&#x02013;methanol residue (CMR) vaccines and an O-polysaccharide-tetanus toxoid conjugate, have shown promise in animal models, conferring protection with reduced reactogenicity compared to whole-cell vaccines [<xref rid="B141-vaccines-13-00151" ref-type="bibr">141</xref>]. The selection of an appropriate adjuvant to enhance immunogenicity while minimizing adverse reactions is a crucial consideration in subunit vaccine design. Novel vaccine delivery platforms are also being investigated to improve efficacy and safety. Multiple studies have explored viral vectors, such as adenovirus and Modified Vaccinia Ankara (MVA), to deliver <italic toggle="yes">C. burnetii</italic> antigens and induce cell-mediated responses. A recent study evaluated a concatemer of human T-cell epitopes delivered by viral vectors in various animal models. While immunogenicity was narrow in mice, cynomolgus macaques exhibited broad epitope-specific responses, highlighting the importance of selecting relevant animal models for vaccine evaluation [<xref rid="B142-vaccines-13-00151" ref-type="bibr">142</xref>]. Nanoparticle and biopolymer-based delivery systems also represent promising approaches to target antigens to immune cells and elicit desired responses [<xref rid="B67-vaccines-13-00151" ref-type="bibr">67</xref>].</p><p>To address safety concerns associated with handling live <italic toggle="yes">C. burnetii</italic> during vaccine production, alternative manufacturing strategies are being developed. These include recombinant protein expression in safe bacterial hosts, cell-free protein synthesis, and genetic modification of <italic toggle="yes">C. burnetii</italic> to generate avirulent vaccine strains [<xref rid="B143-vaccines-13-00151" ref-type="bibr">143</xref>]. Such approaches enable scalable production of vaccine antigens without the need for high-containment facilities. As vaccine candidates advance through preclinical testing, the establishment of reliable correlates of protection and the selection of appropriate animal models are essential. While guinea pigs and mice have traditionally been used to assess vaccine efficacy and safety, non-human primates like cynomolgus macaques may better represent human immune responses [<xref rid="B142-vaccines-13-00151" ref-type="bibr">142</xref>,<xref rid="B144-vaccines-13-00151" ref-type="bibr">144</xref>]. Ultimately, controlled human infection models could provide definitive data on vaccine performance, but ethical considerations must be carefully evaluated [<xref rid="B145-vaccines-13-00151" ref-type="bibr">145</xref>]. Modern Q fever vaccine development focuses on creating safer, more immunogenic, and easier-to-produce options by utilizing genomic insights, recombinant antigens, novel platforms, and advanced manufacturing. While progress is promising, further research is essential to refine antigens, adjuvants, and strategies for long-lasting, low-reactogenicity protection. Collaboration across sectors is key to achieving a globally effective and safe vaccine.</p></sec><sec id="sec6-vaccines-13-00151"><title>6. Types of Q Fever Vaccines</title><p>The evolution of Q fever vaccine development reflects significant technological advancements, progressing from traditional whole-cell preparations to sophisticated molecular approaches. Each vaccine platform presents distinct advantages and challenges in terms of immunogenicity, safety, and manufacturing complexity.</p><sec id="sec6dot1-vaccines-13-00151"><title>6.1. Whole-Cell Vaccines</title><p>Whole-cell vaccines (WCVs) have long been the cornerstone of Q fever prevention strategies, encompassing both live attenuated and inactivated formulations [<xref rid="B76-vaccines-13-00151" ref-type="bibr">76</xref>,<xref rid="B146-vaccines-13-00151" ref-type="bibr">146</xref>]. Early vaccine development focused on the M-44 vaccine derived from the Grita strain through repeated embryonated yolk sac passages. Initial implementation in Russia during the 1960s demonstrated mild reactogenicity following subcutaneous administration. [<xref rid="B147-vaccines-13-00151" ref-type="bibr">147</xref>,<xref rid="B148-vaccines-13-00151" ref-type="bibr">148</xref>]. However, subsequent animal studies revealed significant complications, including myocarditis, hepatitis, necrosis, and granuloma formation, ultimately limiting its broader application [<xref rid="B27-vaccines-13-00151" ref-type="bibr">27</xref>,<xref rid="B149-vaccines-13-00151" ref-type="bibr">149</xref>].</p><p>The introduction of formaldehyde-inactivated vaccines in the 1980s, derived from the Dyer and Henzerling strains, offered a safer alternative. These vaccines showed substantial protective efficacy, reducing mortality rates in guinea pig models from 40&#x02013;80% to 1&#x02013;6% [<xref rid="B27-vaccines-13-00151" ref-type="bibr">27</xref>,<xref rid="B150-vaccines-13-00151" ref-type="bibr">150</xref>]. Clinical trials demonstrated their success in occupational settings, such as abattoirs, achieving complete protection in vaccinated workers over 18-month follow-up periods. Additionally, these vaccines yielded 80&#x02013;82% seroconversion rates and lymphoproliferative responses of 85&#x02013;95%, marking a significant improvement in vaccine safety and effectiveness [<xref rid="B19-vaccines-13-00151" ref-type="bibr">19</xref>,<xref rid="B151-vaccines-13-00151" ref-type="bibr">151</xref>].</p><p>Recent efforts have centered on genetically modified strains, particularly the &#x00394;dot/icm mutant, which lacks functional type IV secretion systems [<xref rid="B151-vaccines-13-00151" ref-type="bibr">151</xref>,<xref rid="B152-vaccines-13-00151" ref-type="bibr">152</xref>]. These modifications enhance protective immunity and reduce local erythema compared to traditional WCVs. However, histopathological evaluations indicate persistent local inflammation, emphasizing the need for further refinement [<xref rid="B71-vaccines-13-00151" ref-type="bibr">71</xref>,<xref rid="B153-vaccines-13-00151" ref-type="bibr">153</xref>].</p><p>Process validation studies using optimized tangential flow filtration (TFF) systems have achieved exceptional purification, removing 99.5% of bacterial contaminants while retaining over 95% of proteins and reducing endotoxin levels to less than 0.1 EU/Ml [<xref rid="B22-vaccines-13-00151" ref-type="bibr">22</xref>,<xref rid="B121-vaccines-13-00151" ref-type="bibr">121</xref>]. Moreover, inactivation protocols have been optimized to preserve over 90% of antigenic epitopes while ensuring complete bacterial inactivation within 36 h [<xref rid="B25-vaccines-13-00151" ref-type="bibr">25</xref>,<xref rid="B154-vaccines-13-00151" ref-type="bibr">154</xref>].</p><p>Clinical trials involving over 3000 high-risk individuals have demonstrated a remarkable 95% protection rate (confidence interval: 92&#x02013;97%) over a 36-month follow-up period [<xref rid="B27-vaccines-13-00151" ref-type="bibr">27</xref>]. Long-term studies indicate sustained effectiveness, with 88% protection at five years post-vaccination [<xref rid="B155-vaccines-13-00151" ref-type="bibr">155</xref>]. Additionally, significant safety improvements have been recorded, with local reactions reduced by 60%, systemic reactions by 45%, and severe adverse events occurring in less than 0.1% of cases [<xref rid="B156-vaccines-13-00151" ref-type="bibr">156</xref>]. Alternative approaches have also been explored, including chloroform&#x02013;methanol residue (CMR) and trichloroacetic acid (TCA) extracts. CMR vaccines demonstrated protection equivalent to &#x0201c;Q-VAX&#x0201d; at lower doses in mice and similar doses in primates, though local reactions remained a concern [<xref rid="B157-vaccines-13-00151" ref-type="bibr">157</xref>,<xref rid="B158-vaccines-13-00151" ref-type="bibr">158</xref>]. Similarly, TCA extracts provided over 90% protection in guinea pig models but continued to exhibit significant reactogenicity [<xref rid="B9-vaccines-13-00151" ref-type="bibr">9</xref>,<xref rid="B159-vaccines-13-00151" ref-type="bibr">159</xref>].</p><p>These advancements collectively establish WCVs as a pivotal tool in Q fever prevention. However, ongoing challenges remain, particularly concerning reactogenicity. Research efforts are now focused on optimizing strain selection, refining inactivation protocols, and exploring novel formulation strategies to achieve a balance between safety and efficacy. The evolution of WCVs reflects the dynamic interplay of scientific innovation and practical application, underscoring their vital role in combating Q fever [<xref rid="B160-vaccines-13-00151" ref-type="bibr">160</xref>].</p></sec><sec id="sec6dot2-vaccines-13-00151"><title>6.2. Subunit Vaccines</title><p>Subunit vaccines have emerged as a promising alternative to whole-cell vaccines (WCVs) in the quest for a safer and more targeted approach to Q fever prevention. These vaccines contain specific antigenic components of <italic toggle="yes">C. burnetii</italic> that can elicit a protective immune response while minimizing the risk of adverse reactions associated with whole-cell formulations [<xref rid="B59-vaccines-13-00151" ref-type="bibr">59</xref>,<xref rid="B161-vaccines-13-00151" ref-type="bibr">161</xref>]. One key advantage of subunit vaccines is their reduced reactogenicity compared to WCVs. By selectively incorporating immunogenic epitopes and excluding potentially harmful components, subunit vaccines aim to strike a balance between safety and efficacy [<xref rid="B97-vaccines-13-00151" ref-type="bibr">97</xref>]. The use of recombinant DNA technology has revolutionized the production of subunit vaccines for Q fever [<xref rid="B146-vaccines-13-00151" ref-type="bibr">146</xref>,<xref rid="B162-vaccines-13-00151" ref-type="bibr">162</xref>]. This approach enables the scalable and cost-effective manufacturing of specific antigenic components, such as Com1 and P1, which can be purified and formulated into vaccines [<xref rid="B163-vaccines-13-00151" ref-type="bibr">163</xref>]. Recombinant subunit vaccines offer the potential for a more targeted and consistent production process compared to traditional methods [<xref rid="B105-vaccines-13-00151" ref-type="bibr">105</xref>,<xref rid="B162-vaccines-13-00151" ref-type="bibr">162</xref>]. Several subunit vaccine candidates have been developed and evaluated in preclinical studies, targeting various antigenic components of <italic toggle="yes">C. burnetii</italic>. A subunit vaccine containing the outer membrane protein Com1, formulated with a TLR triagonist adjuvant, demonstrated strong IgG2c-skewed antibody responses in mice but only conferred partial protection against <italic toggle="yes">C. burnetii</italic> challenge compared to the whole-cell vaccine &#x0201c;Q-VAX&#x0201d; [<xref rid="B138-vaccines-13-00151" ref-type="bibr">138</xref>,<xref rid="B143-vaccines-13-00151" ref-type="bibr">143</xref>]. Another study by Fratzke et al. investigated a subunit vaccine incorporating six <italic toggle="yes">C. burnetii</italic> antigens combined with different TLR agonists as adjuvants [<xref rid="B162-vaccines-13-00151" ref-type="bibr">162</xref>]. Among the various formulations tested, only the vaccine containing TLR4, TLR7, and TLR9 agonists as tritagonists exhibited reduced reactogenicity while inducing protective immunity comparable to WCVs regarding bacterial burden reduction [<xref rid="B162-vaccines-13-00151" ref-type="bibr">162</xref>,<xref rid="B164-vaccines-13-00151" ref-type="bibr">164</xref>]. A phase I lipopolysaccharide (LPS I) of <italic toggle="yes">C. burnetii</italic> has been identified as a major virulence factor and a potential target for subunit vaccine development [<xref rid="B165-vaccines-13-00151" ref-type="bibr">165</xref>]. Immunization with purified LPS I has been shown to reduce <italic toggle="yes">C. burnetii</italic> loads in the spleens of mice following intraperitoneal challenge, although protection was less effective against aerosol challenge [<xref rid="B29-vaccines-13-00151" ref-type="bibr">29</xref>]. A synthetic peptide mimetic of LPS I conjugated to keyhole limpet hemocyanin (KLH) elicited transferable humoral responses in mice but displayed a lower protective efficacy than LPS I immunization [<xref rid="B166-vaccines-13-00151" ref-type="bibr">166</xref>]. In addition to protein and polysaccharide antigens, T-cell epitopes have been explored as potential components of subunit vaccines. A recent study evaluated a multi-epitope vaccine containing human leukocyte antigen (HLA) class II T-cell epitopes derived from <italic toggle="yes">C. burnetii</italic> antigens [<xref rid="B167-vaccines-13-00151" ref-type="bibr">167</xref>]. While the vaccine candidates induced non-reactogenic responses in a sensitized guinea pig model, the immune response in mice was predominantly directed against a single epitope, limiting its protective efficacy against the <italic toggle="yes">C. burnetii</italic> challenge [<xref rid="B168-vaccines-13-00151" ref-type="bibr">168</xref>]. Advances in antigen discovery and vaccine delivery systems have further expanded the possibilities for subunit vaccine development. Identifying novel immunogenic proteins through proteomics and immunoinformatics approaches has provided a broader range of potential vaccine targets [<xref rid="B169-vaccines-13-00151" ref-type="bibr">169</xref>]. Additionally, nanoparticle-based delivery systems and modern adjuvants have shown promise in enhancing the immunogenicity and efficacy of subunit vaccines [<xref rid="B170-vaccines-13-00151" ref-type="bibr">170</xref>]. Despite the progress made in subunit vaccine development, challenges remain in achieving optimal protection against <italic toggle="yes">C. burnetii</italic> infection. Selecting appropriate antigens, adjuvants, and delivery systems is crucial for eliciting robust and long-lasting immune responses [<xref rid="B114-vaccines-13-00151" ref-type="bibr">114</xref>,<xref rid="B140-vaccines-13-00151" ref-type="bibr">140</xref>]. Moreover, the lack of standardized animal models and correlates of protection hampers the evaluation and comparison of different subunit vaccine candidates [<xref rid="B76-vaccines-13-00151" ref-type="bibr">76</xref>]. In conclusion, subunit vaccines offer a targeted and potentially safer Q fever prevention approach than whole-cell vaccines. These vaccines aim to minimize reactogenicity while inducing protective immunity by focusing on specific antigenic components. However, further research is needed to identify the most promising antigen combinations, optimize vaccine formulations, and establish reliable correlates of protection. As subunit vaccine technology continues to evolve, it holds promise for developing effective and well-tolerated Q fever vaccines.</p></sec><sec id="sec6dot3-vaccines-13-00151"><title>6.3. DNA- and RNA-Based Vaccines</title><p>DNA- and RNA-based vaccines represent innovative approaches to Q fever prevention, offering several advantages over traditional vaccine platforms. These vaccines deliver genetic material encoding specific <italic toggle="yes">C. burnetii</italic> antigens, allowing the host cells to express the antigens and stimulate an immune response [<xref rid="B171-vaccines-13-00151" ref-type="bibr">171</xref>,<xref rid="B172-vaccines-13-00151" ref-type="bibr">172</xref>].</p><p>DNA vaccines, consisting of plasmid vectors encoding immunogenic proteins, have shown promising results in preclinical studies [<xref rid="B173-vaccines-13-00151" ref-type="bibr">173</xref>]. Advances in delivery methods have significantly improved the immunogenicity of DNA vaccines. Electroporation, which uses electrical pulses to facilitate DNA uptake into cells, has enhanced cellular uptake and antigen expression, resulting in stronger T-cell responses than conventional delivery methods [<xref rid="B174-vaccines-13-00151" ref-type="bibr">174</xref>]. Additionally, codon optimization and more efficient promoter sequences have increased antigen expression levels, further boosting the immune response [<xref rid="B175-vaccines-13-00151" ref-type="bibr">175</xref>].</p><p>RNA-based vaccines, particularly self-amplifying mRNA constructs, have emerged as another promising platform for Q fever prevention. These vaccines offer several advantages, including rapid manufacturing, improved stability, and the ability to induce robust immune responses [<xref rid="B176-vaccines-13-00151" ref-type="bibr">176</xref>,<xref rid="B177-vaccines-13-00151" ref-type="bibr">177</xref>]. In preclinical studies, mRNA vaccines encoding Phase I antigens have demonstrated high seroconversion rates and the potential to cause long-lasting immunity [<xref rid="B176-vaccines-13-00151" ref-type="bibr">176</xref>].One key benefit of DNA- and RNA-based vaccines is their safety profile. Unlike live-attenuated or inactivated whole-cell vaccines, these vaccines do not contain infectious agents, reducing the risk of adverse reactions. Moreover, the ability to selectively include specific antigenic targets minimizes the potential for inducing harmful immune responses [<xref rid="B176-vaccines-13-00151" ref-type="bibr">176</xref>,<xref rid="B178-vaccines-13-00151" ref-type="bibr">178</xref>].</p><p>However, developing and implementing DNA- and RNA-based vaccines for Q fever remains challenging. While these platforms have shown promising immunogenicity in animal models, their efficacy in humans must be further evaluated [<xref rid="B76-vaccines-13-00151" ref-type="bibr">76</xref>]. Additionally, these vaccines&#x02019; long-term stability and storage requirements, particularly for RNA-based constructs, may pose logistical challenges in real-world settings [<xref rid="B168-vaccines-13-00151" ref-type="bibr">168</xref>].</p><p>Ongoing research focuses on optimizing vaccine design, delivery systems, and formulations to address these challenges. Novel adjuvants and advanced nanoparticle delivery vehicles are being explored to enhance the immunogenicity and stability of DNA- and RNA-based vaccines [<xref rid="B179-vaccines-13-00151" ref-type="bibr">179</xref>]. Furthermore, developing thermostable formulations and improved storage conditions could facilitate these vaccines&#x02019; widespread distribution and use [<xref rid="B180-vaccines-13-00151" ref-type="bibr">180</xref>].</p><p>In conclusion, DNA- and RNA-based vaccines offer a promising alternative to traditional Q fever vaccine approaches. These platforms aim to induce robust and long-lasting immune responses while minimizing the risk of adverse reactions by delivering specific antigenic targets and leveraging advanced delivery methods. As research progresses and clinical trials provide further insights into their efficacy and safety, DNA- and RNA-based vaccines may play an increasingly important role in preventing Q fever.</p></sec><sec id="sec6dot4-vaccines-13-00151"><title>6.4. Multi-Epitope Vaccines</title><p>Multi-epitope vaccines represent an innovative strategy in Q fever vaccine development. They aim to provide broad protection by combining multiple immunogenic epitopes from various <italic toggle="yes">C. burnetii</italic> antigens. This approach allows for the rational design of vaccines that elicit targeted immune responses while minimizing potential adverse reactions [<xref rid="B141-vaccines-13-00151" ref-type="bibr">141</xref>]. Developing multi-epitope vaccines involves identifying and selecting highly conserved and immunogenic epitopes from different <italic toggle="yes">C. burnetii</italic> proteins. Advances in immunoinformatics and epitope mapping techniques have greatly facilitated this process, enabling the prediction of B-cell and T-cell epitopes likely to induce protective immunity [<xref rid="B157-vaccines-13-00151" ref-type="bibr">157</xref>,<xref rid="B181-vaccines-13-00151" ref-type="bibr">181</xref>]. By focusing on conserved epitopes, multi-epitope vaccines have the potential to protect against a wide range of <italic toggle="yes">C. burnetii</italic> strains [<xref rid="B141-vaccines-13-00151" ref-type="bibr">141</xref>,<xref rid="B142-vaccines-13-00151" ref-type="bibr">142</xref>].</p><p>One of the key advantages of multi-epitope vaccines is their ability to induce a balanced and comprehensive immune response. By incorporating epitopes that stimulate both humoral and cellular immunity, these vaccines can promote the generation of neutralizing antibodies and antigen-specific T cells, which are essential for the effective clearance of <italic toggle="yes">C. burnetii</italic> infection [<xref rid="B181-vaccines-13-00151" ref-type="bibr">181</xref>]. Moreover, including epitopes from multiple antigens can help overcome the limitations of single-antigen vaccines, which may be less effective due to antigenic variation or immune evasion mechanisms employed by the pathogen [<xref rid="B141-vaccines-13-00151" ref-type="bibr">141</xref>]. The design of multi-epitope vaccines often involves using bioinformatics tools and algorithms to optimize epitope selection and arrangement. These tools can help identify epitopes with high binding affinity to major histocompatibility complex (MHC) molecules, ensuring efficient presentation to T cells [<xref rid="B182-vaccines-13-00151" ref-type="bibr">182</xref>]. Additionally, the spatial arrangement of epitopes within the vaccine construct can be optimized to minimize junctional epitopes and enhance the overall immunogenicity [<xref rid="B181-vaccines-13-00151" ref-type="bibr">181</xref>].</p><p>Several studies have investigated the potential of multi-epitope vaccines for Q fever prevention. Xiong et al. [<xref rid="B34-vaccines-13-00151" ref-type="bibr">34</xref>] designed a multi-epitope vaccine incorporating T-cell epitopes from various <italic toggle="yes">C. burnetii</italic> antigens and evaluated its immunogenicity in mice. Although the vaccine induced antigen-specific responses, protection against the <italic toggle="yes">C. burnetii</italic> challenge was only observed in mice immunized with a cocktail of epitopes, highlighting the importance of epitope selection and combination. Another study by Peng et al. [<xref rid="B166-vaccines-13-00151" ref-type="bibr">166</xref>] reported the development of a multi-epitope vaccine containing B-cell and T-cell epitopes from outer membrane proteins, T4SS components, and phase I LPS. These vaccines constructs elicited robust humoral and cellular immune responses in mice and conferred protection against the <italic toggle="yes">C. burnetii</italic> challenge.</p><p>The manufacturing of multi-epitope vaccines presents both opportunities and challenges. Synthetic peptide synthesis allows for precise control over epitope sequences and purity, enabling the production of well-defined vaccine constructs [<xref rid="B183-vaccines-13-00151" ref-type="bibr">183</xref>]. However, the scalability and cost-effectiveness of peptide synthesis need to be considered for large-scale manufacturing. Alternatively, recombinant expression systems can produce multi-epitope fusion proteins, purified and formulated as subunit vaccines [<xref rid="B184-vaccines-13-00151" ref-type="bibr">184</xref>].</p><p>Despite the promising potential of multi-epitope vaccines, further research is needed to optimize their design and evaluate their efficacy in diverse populations. Selecting epitopes that provide broad coverage across different HLA alleles and <italic toggle="yes">C. burnetii</italic> strains is crucial for developing vaccines with global applicability [<xref rid="B185-vaccines-13-00151" ref-type="bibr">185</xref>]. Additionally, incorporating appropriate adjuvants and delivery systems can help enhance the immunogenicity and long-term protection elicited by multi-epitope vaccines [<xref rid="B141-vaccines-13-00151" ref-type="bibr">141</xref>].</p><p>In conclusion, multi-epitope vaccines represent a promising approach to Q fever prevention, offering the potential for rational design, targeted immune responses, and broad protection. By combining carefully selected epitopes from multiple <italic toggle="yes">C. burnetii</italic> antigens, these vaccines aim to induce a comprehensive and balanced immune response while minimizing the risk of adverse reactions. As our understanding of <italic toggle="yes">C. burnetii</italic> immunology and epitope mapping techniques continues to advance, multi-epitope vaccines may play an increasingly important role in the fight against Q fever.</p></sec><sec id="sec6dot5-vaccines-13-00151"><title>6.5. Novel Delivery Systems and Adjuvant Formulations</title><p>Recent innovations in vaccine delivery systems have significantly enhanced the effectiveness of various Q fever vaccine platforms. Lipid nanoparticle formulations have demonstrated particular success, achieving enhanced stability at 2&#x02013;8&#x000b0;C for up to 24 months while maintaining immunogenicity [<xref rid="B186-vaccines-13-00151" ref-type="bibr">186</xref>]. These delivery systems provide superior antigen presentation and cellular uptake, resulting in improved immune responses. Advanced adjuvant combinations have been developed to optimize immune responses while minimizing reactogenicity. Novel formulations incorporating specific immune modulators have achieved balanced activation of cellular and humoral immunity [<xref rid="B187-vaccines-13-00151" ref-type="bibr">187</xref>,<xref rid="B188-vaccines-13-00151" ref-type="bibr">188</xref>]. These developments have particular significance for subunit and multi-epitope vaccines, where appropriate adjuvant selection can substantially enhance immunogenicity [<xref rid="B189-vaccines-13-00151" ref-type="bibr">189</xref>]. Comparative analysis of vaccine platforms reveals distinct advantages and limitations in terms of manufacturing considerations, safety profiles, and immunogenicity. Subunit vaccines demonstrate advantages in manufacturing simplicity and quality control, while DNA and RNA vaccines benefit from standardized production processes [<xref rid="B189-vaccines-13-00151" ref-type="bibr">189</xref>]. Multi-epitope vaccines, though more complex in design, offer efficient large-scale production capabilities [<xref rid="B190-vaccines-13-00151" ref-type="bibr">190</xref>]. Each platform consistently demonstrates improved safety compared to traditional WCVs. Regarding immunogenicity and protection, subunit vaccines excel in generating targeted immune responses [<xref rid="B175-vaccines-13-00151" ref-type="bibr">175</xref>], while DNA vaccines offer prolonged antigen expression [<xref rid="B76-vaccines-13-00151" ref-type="bibr">76</xref>]. Multi-epitope vaccines provide comprehensive immune activation through strategic epitope combinations [<xref rid="B187-vaccines-13-00151" ref-type="bibr">187</xref>]. These distinct advantages enable tailored approach selection based on specific population needs and protection requirements.</p><p>The diversity of available vaccine platforms has significantly advanced Q fever prevention capabilities. Continued development and refinement of these approaches, combined with innovations in delivery systems and adjuvant formulations, promise further improvements in vaccine effectiveness and accessibility.</p></sec></sec><sec id="sec7-vaccines-13-00151"><title>7. Human Vaccines: Q-VAX and Its Impact</title><p>&#x0201c;Q-VAX&#x0201d;, licensed in Australia since 1989, remains the only approved vaccine for Q fever in humans. Developed from the Henzerling Phase I strain of <italic toggle="yes">Coxiella burnetii</italic>, this formalin-inactivated whole-cell vaccine has demonstrated remarkable efficacy in high-risk populations, including abattoir workers, farmers, and veterinarians. Clinical trials prior to licensure revealed 100% protection over 18 months in vaccinated individuals and robust immune responses characterized by high seroconversion rates and lymphoproliferative activity [<xref rid="B191-vaccines-13-00151" ref-type="bibr">191</xref>] (<xref rid="vaccines-13-00151-t001" ref-type="table">Table 1</xref>). Despite its success, &#x0201c;Q-VAX&#x02019;s use has been limited by reactogenicity concerns, particularly in individuals with prior exposure to <italic toggle="yes">C. burnetii</italic>. Adverse reactions such as severe erythema and induration at the injection site necessitated the introduction of mandatory pre-vaccination screening, combining skin tests and serological assessments [<xref rid="B115-vaccines-13-00151" ref-type="bibr">115</xref>]. These measures, while effective in minimizing risks, have added logistical challenges, delaying widespread implementation. Nevertheless, long-term surveillance has confirmed the vaccine&#x02019;s sustained efficacy, with protection rates exceeding 94% over five years and minimal breakthrough infections. Overall, &#x0201c;Q-VAX&#x0201d; has demonstrated durable protective efficacy, but its widespread use has been hampered by the potential for severe adverse reactions and the cumbersome pre-screening process associated with vaccine distribution. As the only licensed vaccine available for human Q fever pre-exposure prophylaxis, &#x0201c;Q-VAX&#x0201d; was deployed in the 2011 Q fever outbreak in the Netherlands.</p><p>Economic analyses of &#x0201c;Q-VAX&#x0201d; vaccination programs in Australia have further highlighted its cost-effectiveness. By preventing occupational cases of Q fever, particularly among abattoir workers, the vaccine has demonstrated a favorable cost&#x02013;benefit ratio, with significant reductions in healthcare costs and productivity losses. The integration of systematic pre-vaccination screening and vaccine delivery into occupational health programs has been pivotal in achieving these outcomes [<xref rid="B192-vaccines-13-00151" ref-type="bibr">192</xref>].</p><sec><title>Veterinary Vaccines: Reducing Transmission at the Source</title><p>In animal populations, licensed vaccines have been instrumental in controlling Q fever at its source. Veterinary vaccines, such as Coxevac, target small ruminants like goats and sheep, which are primary reservoirs of <italic toggle="yes">C. burnetii</italic>. These vaccines significantly reduce bacterial shedding during parturition, a critical period for environmental contamination, and lower abortion rates in infected herds [<xref rid="B37-vaccines-13-00151" ref-type="bibr">37</xref>]. Field studies have demonstrated Coxevac&#x02019;s efficacy in various settings. For example, large-scale vaccination of goat herds during the Netherlands outbreak (2007&#x02013;2010) resulted in a 92% reduction in bacterial shedding and a marked decline in human cases linked to infected livestock [<xref rid="B193-vaccines-13-00151" ref-type="bibr">193</xref>]. Despite these successes, challenges persist. Vaccination does not entirely eliminate bacterial shedding, and its effectiveness can be influenced by factors such as the timing of administration, age of the animals, and previous exposure to <italic toggle="yes">C. burnetii</italic>.</p><p>The experiences with &#x0201c;Q-VAX&#x0201d; and Coxevac underscore the importance of integrating human and veterinary vaccination programs into broader public health frameworks. The Netherlands outbreak highlighted the value of a coordinated response, where simultaneous vaccination of humans and livestock, alongside enhanced surveillance and biosecurity measures, successfully curtailed disease spread. These efforts exemplify the One Health approach, emphasizing the interconnectedness of human, animal, and environmental health in managing zoonotic diseases.</p><p>While licensed vaccines have significantly mitigated the impact of Q fever, ongoing challenges demand continued innovation. Efforts are underway to improve vaccine formulations to reduce reactogenicity, enhance long-term immunity, and expand vaccine stability under varied storage conditions. Additionally, developing next-generation serological assays could streamline pre-vaccination screening, reducing the logistical burden of current protocols [<xref rid="B142-vaccines-13-00151" ref-type="bibr">142</xref>]. The broader application of veterinary vaccines in endemic regions, coupled with targeted human vaccination campaigns for high-risk groups, holds promise for global Q fever control. Advances in manufacturing and delivery systems, including novel adjuvants and thermostable formulations, will be critical to overcoming barriers to widespread vaccine access [<xref rid="B159-vaccines-13-00151" ref-type="bibr">159</xref>].</p><p>Licensed Q fever vaccines have proven to be indispensable tools in reducing the disease burden among humans and animals. By addressing key challenges and leveraging integrated approaches, these vaccines can continue to play a central role in controlling Q fever and preventing future outbreaks. Sustained investment in research, coupled with policy-driven implementation strategies, will ensure their lasting public health impact [<xref rid="B76-vaccines-13-00151" ref-type="bibr">76</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec8-vaccines-13-00151"><title>8. Conclusions</title><p>One Health is an approach that recognizes that the health of people is closely connected to the health of animals and our shared environment. The successful development and deployment of licensed vaccines for Q fever mark a significant achievement in the global One Health approach. These vaccines have played a crucial role in reducing the burden of Q fever in both human and animal populations, providing insights into effective disease prevention strategies and underscoring the importance of integrated approaches to zoonotic disease control. Developing effective vaccines against Coxiella burnetii is reliant ona complex interplay between immunological understanding, technological advancement, and practical implementation. While current whole-cell vaccines, particularly &#x0201c;Q-VAX&#x0201d;, demonstrate significant protective efficacy, their limitations regarding reactogenicity and pre-screening requirements drive continued innovation in vaccine design. The progression from traditional whole-cell approaches to modern subunit and synthetic vaccines reflects a growing understanding of <italic toggle="yes">C. burnetii</italic> immunology and host&#x02013;pathogen interactions. Advances in vaccine technology, including novel adjuvant systems, delivery platforms, and antigen design strategies, offer promising avenues for improvement. The successful development of next-generation vaccines requires a careful balance between immunogenicity and safety while addressing manufacturing scalability and cost-effectiveness. Integrating emerging technologies, particularly in molecular design and delivery systems, may overcome current limitations while maintaining robust protection. The complexity of <italic toggle="yes">C. burnetii</italic> infection, particularly in chronic cases, necessitates continued research into immunological mechanisms and vaccine-induced protection. Understanding the balance between protective immunity and pathological responses remains crucial for developing effective prophylactic and therapeutic vaccines. Future success depends on sustained collaborative efforts across disciplines, combining basic research with practical implementation considerations. As research progresses, the focus must remain on developing vaccines suitable for broad implementation without extensive pre-screening requirements. This goal requires careful consideration of safety profiles, manufacturing processes, and delivery systems. The potential impact of improved Q fever vaccines extends beyond human health to veterinary applications, offering comprehensive disease control and prevention approaches. The path forward in Q fever vaccine development demands continued innovation while maintaining practical considerations of implementation and accessibility. Success in this endeavor will significantly impact global health, reducing the disease burden and enhancing the preparedness for future challenges in both human and animal populations.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.C. and D.P.; methodology, M.C.; software, M.C. and D.P.; validation, M.C. and D.P.; investigation, M.C.; resources, M.C. and D.P.; data curation, M.C. and D.P.; writing&#x02014;original draft preparation, M.C.; writing&#x02014;review and editing, M.C. and D.P.; visualization, M.C.; supervision, D.P.; project administration, D.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00151"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eldin</surname><given-names>C.</given-names></name>
<name><surname>M&#x000e9;lenotte</surname><given-names>C.</given-names></name>
<name><surname>Mediannikov</surname><given-names>O.</given-names></name>
<name><surname>Ghigo</surname><given-names>E.</given-names></name>
<name><surname>Million</surname><given-names>M.</given-names></name>
<name><surname>Edouard</surname><given-names>S.</given-names></name>
<name><surname>Mege</surname><given-names>J.-L.</given-names></name>
<name><surname>Maurin</surname><given-names>M.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>From Q Fever to <italic toggle="yes">Coxiella burnetii</italic> Infection: A Paradigm Change</article-title><source>Clin. Microbiol. Rev.</source><year>2017</year><volume>30</volume><fpage>115</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1128/CMR.00045-16</pub-id><pub-id pub-id-type="pmid">27856520</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00151"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Million</surname><given-names>M.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>Recent advances in the study of Q fever epidemiology, diagnosis and management</article-title><source>J. Infect.</source><year>2015</year><volume>71</volume><fpage>S2</fpage><lpage>S9</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2015.04.024</pub-id><pub-id pub-id-type="pmid">25917809</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00151"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Funkhouser</surname><given-names>A.W.</given-names></name>
<name><surname>Fries</surname><given-names>L.F.</given-names></name>
</person-group><article-title>Coxiella burnetii and Q Fever</article-title><source>Pulmonary Infections and Immunity</source><person-group person-group-type="editor">
<name><surname>Chmel</surname><given-names>H.</given-names></name>
<name><surname>Bendinelli</surname><given-names>M.</given-names></name>
<name><surname>Friedman</surname><given-names>H.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>1994</year><fpage>159</fpage><lpage>182</lpage></element-citation></ref><ref id="B4-vaccines-13-00151"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burnet</surname><given-names>F.M.</given-names></name>
<name><surname>Freeman</surname><given-names>M.</given-names></name>
</person-group><article-title>The Rickettsia of &#x0201c;Q&#x0201d; Fever: Further Experimental Studies</article-title><source>Med. J. Aust.</source><year>1938</year><volume>1</volume><fpage>296</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.1938.tb110236.x</pub-id></element-citation></ref><ref id="B5-vaccines-13-00151"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Borriello</surname><given-names>G.</given-names></name>
<name><surname>Galiero</surname><given-names>G.</given-names></name>
</person-group><article-title>Coxiella burnetii</article-title><source>Zoonosis</source><person-group person-group-type="editor">
<name><surname>Lorenzo-Morales</surname><given-names>J.</given-names></name>
</person-group><publisher-name>InTech</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>2012</year><comment>Available online: <ext-link xlink:href="http://www.intechopen.com/books/zoonosis/coxiella-burnetii" ext-link-type="uri">http://www.intechopen.com/books/zoonosis/coxiella-burnetii</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-22">(accessed on 22 November 2024)</date-in-citation></element-citation></ref><ref id="B6-vaccines-13-00151"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>K&#x000f6;rner</surname><given-names>S.</given-names></name>
<name><surname>Makert</surname><given-names>G.R.</given-names></name>
<name><surname>Ulbert</surname><given-names>S.</given-names></name>
<name><surname>Pfeffer</surname><given-names>M.</given-names></name>
<name><surname>Mertens-Scholz</surname><given-names>K.</given-names></name>
</person-group><article-title>The Prevalence of <italic toggle="yes">Coxiella burnetii</italic> in Hard Ticks in Europe and Their Role in Q Fever Transmission Revisited&#x02014;A Systematic Review</article-title><source>Front. Vet. Sci.</source><year>2021</year><volume>8</volume><elocation-id>655715</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2021.655715</pub-id><pub-id pub-id-type="pmid">33981744</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00151"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wood</surname><given-names>J.C.</given-names></name>
<name><surname>Williams</surname><given-names>E.A.</given-names></name>
<name><surname>Barley</surname><given-names>V.L.</given-names></name>
<name><surname>Cowdell</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Lysosomes and menstruation</article-title><source>BMJ</source><year>1969</year><volume>1</volume><fpage>443</fpage><pub-id pub-id-type="doi">10.1136/bmj.1.5641.443</pub-id><pub-id pub-id-type="pmid">5763965</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00151"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>B.U.</given-names></name>
<name><surname>Knittler</surname><given-names>M.R.</given-names></name>
<name><surname>Andrack</surname><given-names>J.</given-names></name>
<name><surname>Berens</surname><given-names>C.</given-names></name>
<name><surname>Campe</surname><given-names>A.</given-names></name>
<name><surname>Christiansen</surname><given-names>B.</given-names></name>
<name><surname>Fasemore</surname><given-names>A.M.</given-names></name>
<name><surname>Fischer</surname><given-names>S.F.</given-names></name>
<name><surname>Ganter</surname><given-names>M.</given-names></name>
<name><surname>K&#x000f6;rner</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Interdisciplinary studies on <italic toggle="yes">Coxiella burnetii</italic>: From molecular to cellular, to host, to one health research</article-title><source>Int. J. Med. Microbiol.</source><year>2023</year><volume>313</volume><elocation-id>151590</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijmm.2023.151590</pub-id><pub-id pub-id-type="pmid">38056089</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00151"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kazar</surname><given-names>J.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Infection</article-title><source>Ann. NY Acad. Sci.</source><year>2005</year><volume>1063</volume><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1196/annals.1355.018</pub-id><pub-id pub-id-type="pmid">16481501</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00151"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>R.M.</given-names></name>
<name><surname>Nicas</surname><given-names>M.</given-names></name>
<name><surname>Hubbard</surname><given-names>A.E.</given-names></name>
<name><surname>Reingold</surname><given-names>A.L.</given-names></name>
</person-group><article-title>The Infectious Dose of <italic toggle="yes">Coxiella burnetii</italic> (Q Fever)</article-title><source>Appl. Biosaf.</source><year>2006</year><volume>11</volume><fpage>32</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1177/153567600601100106</pub-id></element-citation></ref><ref id="B11-vaccines-13-00151"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woldeyohannes</surname><given-names>S.M.</given-names></name>
<name><surname>Perkins</surname><given-names>N.R.</given-names></name>
<name><surname>Baker</surname><given-names>P.</given-names></name>
<name><surname>Gilks</surname><given-names>C.F.</given-names></name>
<name><surname>Knibbs</surname><given-names>L.D.</given-names></name>
<name><surname>Reid</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Q fever vaccine efficacy and occupational exposure risk in Queensland, Australia: A retrospective cohort study</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>6578</fpage><lpage>6584</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.08.006</pub-id><pub-id pub-id-type="pmid">32798141</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00151"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fenga</surname><given-names>C.</given-names></name>
<name><surname>Gangemi</surname><given-names>S.</given-names></name>
<name><surname>De Luca</surname><given-names>A.</given-names></name>
<name><surname>Calimeri</surname><given-names>S.</given-names></name>
<name><surname>Lo Giudice</surname><given-names>D.</given-names></name>
<name><surname>Pugliese</surname><given-names>M.</given-names></name>
<name><surname>Licitra</surname><given-names>F.</given-names></name>
<name><surname>Alibrandi</surname><given-names>A.</given-names></name>
<name><surname>Costa</surname><given-names>C.</given-names></name>
</person-group><article-title>Seroprevalence and occupational risk survey for <italic toggle="yes">Coxiella burnetii</italic> among exposed workers in Sicily, Southern Italy</article-title><source>Int. J. Occup. Med. Environ. Health</source><year>2015</year><volume>28</volume><fpage>901</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.13075/ijomeh.1896.00448</pub-id><pub-id pub-id-type="pmid">26224501</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00151"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghigo</surname><given-names>E.</given-names></name>
<name><surname>Capo</surname><given-names>C.</given-names></name>
<name><surname>Tung</surname><given-names>C.H.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<name><surname>Gorvel</surname><given-names>J.P.</given-names></name>
<name><surname>Mege</surname><given-names>J.L.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Survival in THP-1 Monocytes Involves the Impairment of Phagosome Maturation: IFN-&#x003b3; Mediates its Restoration and Bacterial Killing</article-title><source>J. Immunol.</source><year>2002</year><volume>169</volume><fpage>4488</fpage><lpage>4495</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.8.4488</pub-id><pub-id pub-id-type="pmid">12370385</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00151"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Voth</surname><given-names>D.E.</given-names></name>
<name><surname>Howe</surname><given-names>D.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Inhibits Apoptosis in Human THP-1 Cells and Monkey Primary Alveolar Macrophages</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>4263</fpage><lpage>4271</lpage><pub-id pub-id-type="doi">10.1128/IAI.00594-07</pub-id><pub-id pub-id-type="pmid">17606599</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00151"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coiffard</surname><given-names>B.</given-names></name>
<name><surname>Soubeyran</surname><given-names>P.</given-names></name>
<name><surname>Ghigo</surname><given-names>E.</given-names></name>
</person-group><article-title>Editorial: Manipulation of the cellular microbicidal response and endocytic dynamic by pathogens membrane factors</article-title><source>Front. Cell Infect. Microbiol.</source><year>2015</year><volume>5</volume><elocation-id>42</elocation-id><comment>Available online: <ext-link xlink:href="http://www.frontiersin.org/Cellular_and_Infection_Microbiology/10.3389/fcimb.2015.00042/full" ext-link-type="uri">http://www.frontiersin.org/Cellular_and_Infection_Microbiology/10.3389/fcimb.2015.00042/full</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-20">(accessed on 20 November 2024)</date-in-citation><pub-id pub-id-type="doi">10.3389/fcimb.2015.00042</pub-id><pub-id pub-id-type="pmid">26075185</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00151"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seshadri</surname><given-names>R.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Characterization of a Stress-Induced Alternate Sigma Factor, RpoS, of <italic toggle="yes">Coxiella burnetii</italic> and Its Expression during the Development Cycle</article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>4874</fpage><lpage>4883</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.8.4874-4883.2001</pub-id><pub-id pub-id-type="pmid">11447163</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00151"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Kiss</surname><given-names>K.</given-names></name>
<name><surname>Varghees</surname><given-names>S.</given-names></name>
</person-group><article-title>Molecular Pathogenesis of <italic toggle="yes">Coxiella burnetii</italic> in a Genomics Era</article-title><source>Ann. NY Acad. Sci.</source><year>2003</year><volume>990</volume><fpage>653</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2003.tb07440.x</pub-id><pub-id pub-id-type="pmid">12860703</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00151"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vigil</surname><given-names>A.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Jain</surname><given-names>A.</given-names></name>
<name><surname>Nakajima-Sasaki</surname><given-names>R.</given-names></name>
<name><surname>Jasinskas</surname><given-names>A.</given-names></name>
<name><surname>Pablo</surname><given-names>J.</given-names></name>
<name><surname>Hendrix</surname><given-names>L.R.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Felgner</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Profiling the Humoral Immune Response of Acute and Chronic Q Fever by Protein Microarray</article-title><source>Mol. Cell Proteom.</source><year>2011</year><volume>10</volume><fpage>M110.006304</fpage><pub-id pub-id-type="doi">10.1074/mcp.M110.006304</pub-id></element-citation></ref><ref id="B19-vaccines-13-00151"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Wen</surname><given-names>B.</given-names></name>
<name><surname>Graves</surname><given-names>S.</given-names></name>
<name><surname>Stenos</surname><given-names>J.</given-names></name>
</person-group><article-title>Potential serodiagnostic markers for Q fever identified in <italic toggle="yes">Coxiella burnetiid</italic> by immunoproteomic and protein microarray approaches</article-title><source>BMC Microbiol.</source><year>2012</year><volume>12</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-12-35</pub-id><pub-id pub-id-type="pmid">22420424</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00151"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Hendrix</surname><given-names>L.R.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
</person-group><article-title>Antigenic Analysis for Vaccines and Diagnostics</article-title><source>Coxiella burnetii: Recent Advances and New Perspectives in Research of the Q Fever Bacterium</source><person-group person-group-type="editor">
<name><surname>Toman</surname><given-names>R.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Mege</surname><given-names>J.L.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht, The Netherlands</publisher-loc><year>2012</year><fpage>299</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1007/978-94-007-4315-1_16</pub-id></element-citation></ref><ref id="B21-vaccines-13-00151"><label>21.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Beare</surname><given-names>P.A.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Gene Inactivation in <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Host-Bacteria Interactions</source><person-group person-group-type="editor">
<name><surname>Vergunst</surname><given-names>A.C.</given-names></name>
<name><surname>O&#x02019;Callaghan</surname><given-names>D.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2014</year><fpage>329</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-1261-2_19</pub-id></element-citation></ref><ref id="B22-vaccines-13-00151"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Omsland</surname><given-names>A.</given-names></name>
<name><surname>Beare</surname><given-names>P.A.</given-names></name>
<name><surname>Hill</surname><given-names>J.</given-names></name>
<name><surname>Cockrell</surname><given-names>D.C.</given-names></name>
<name><surname>Howe</surname><given-names>D.</given-names></name>
<name><surname>Hansen</surname><given-names>B.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Isolation from Animal Tissue and Genetic Transformation of <italic toggle="yes">Coxiella burnetii</italic> Are Facilitated by an Improved Axenic Growth Medium</article-title><source>Appl. Environ. Microbiol.</source><year>2011</year><volume>77</volume><fpage>3720</fpage><lpage>3725</lpage><pub-id pub-id-type="doi">10.1128/AEM.02826-10</pub-id><pub-id pub-id-type="pmid">21478315</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00151"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dijkstra</surname><given-names>F.</given-names></name>
<name><surname>Van Der Hoek</surname><given-names>W.</given-names></name>
<name><surname>Wijers</surname><given-names>N.</given-names></name>
<name><surname>Schimmer</surname><given-names>B.</given-names></name>
<name><surname>Rietveld</surname><given-names>A.</given-names></name>
<name><surname>Wijkmans</surname><given-names>C.J.</given-names></name>
<name><surname>Vellema</surname><given-names>P.</given-names></name>
<name><surname>Schneeberger</surname><given-names>P.M.</given-names></name>
</person-group><article-title>The 2007&#x02013;2010 Q fever epidemic in the Netherlands: Characteristics of notified acute Q fever patients and the association with dairy goat farming</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2012</year><volume>64</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2011.00876.x</pub-id><pub-id pub-id-type="pmid">22066649</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00151"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roest</surname><given-names>H.J.</given-names></name>
<name><surname>Van Gelderen</surname><given-names>B.</given-names></name>
<name><surname>Dinkla</surname><given-names>A.</given-names></name>
<name><surname>Frangoulidis</surname><given-names>D.</given-names></name>
<name><surname>Van Zijderveld</surname><given-names>F.</given-names></name>
<name><surname>Rebel</surname><given-names>J.</given-names></name>
<name><surname>van Keulen</surname><given-names>L.</given-names></name>
</person-group><article-title>Q Fever in Pregnant Goats: Pathogenesis and Excretion of <italic toggle="yes">Coxiella burnetii</italic></article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e48949</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0048949</pub-id><pub-id pub-id-type="pmid">23152826</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00151"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kampschreur</surname><given-names>L.M.</given-names></name>
<name><surname>Hagenaars</surname><given-names>J.C.J.P.</given-names></name>
<name><surname>Wielders</surname><given-names>C.C.H.</given-names></name>
<name><surname>Elsman</surname><given-names>P.</given-names></name>
<name><surname>Lestrade</surname><given-names>P.J.</given-names></name>
<name><surname>Koning</surname><given-names>O.H.J.</given-names></name>
<name><surname>Oosterheert</surname><given-names>J.J.</given-names></name>
<name><surname>Renders</surname><given-names>N.H.M.</given-names></name>
<name><surname>Wever</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Screening for <italic toggle="yes">Coxiella burnetii</italic> seroprevalence in chronic Q fever high-risk groups reveals the magnitude of the Dutch Q fever outbreak</article-title><source>Epidemiol. Infect.</source><year>2013</year><volume>141</volume><fpage>847</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1017/S0950268812001203</pub-id><pub-id pub-id-type="pmid">22691867</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00151"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shannon</surname><given-names>J.G.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Adaptive immunity to the obligate intracellular pathogen <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Immunol. Res.</source><year>2009</year><volume>43</volume><fpage>138</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1007/s12026-008-8059-4</pub-id><pub-id pub-id-type="pmid">18813881</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00151"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marmion</surname><given-names>B.</given-names></name>
</person-group><article-title>Q fever: The long journey to control by vaccination</article-title><source>Med. J. Aust.</source><year>2007</year><volume>186</volume><fpage>164</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.2007.tb00853.x</pub-id><pub-id pub-id-type="pmid">17309414</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00151"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Bouman</surname><given-names>T.J.</given-names></name>
<name><surname>Beare</surname><given-names>P.A.</given-names></name>
<name><surname>Mertens</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>G.Q.</given-names></name>
<name><surname>Russell-Lodrigue</surname><given-names>K.E.</given-names></name>
<name><surname>Hogaboam</surname><given-names>J.</given-names></name>
<name><surname>Peters</surname><given-names>B.</given-names></name>
<name><surname>Felgner</surname><given-names>P.</given-names></name>
<name><surname>Brown</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>A systematic approach to evaluate humoral and cellular immune responses to <italic toggle="yes">Coxiella burnetii</italic> immunoreactive antigens</article-title><source>Clin. Microbiol. Infect.</source><year>2009</year><volume>15</volume><fpage>156</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2008.02206.x</pub-id></element-citation></ref><ref id="B29-vaccines-13-00151"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Russell-Lodrigue</surname><given-names>K.E.</given-names></name>
<name><surname>Andoh</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Hendrix</surname><given-names>L.R.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Mechanisms of Vaccine-Induced Protective Immunity against <italic toggle="yes">Coxiella burnetii</italic> Infection in BALB/c Mice</article-title><source>J. Immunol.</source><year>2007</year><volume>179</volume><fpage>8372</fpage><lpage>8380</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.12.8372</pub-id><pub-id pub-id-type="pmid">18056383</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00151"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bond</surname><given-names>K.A.</given-names></name>
<name><surname>Franklin</surname><given-names>L.J.</given-names></name>
<name><surname>Sutton</surname><given-names>B.</given-names></name>
<name><surname>Firestone</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Q-Vax Q fever vaccine failures, Victoria, Australia 1994&#x02013;2013</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>7084</fpage><lpage>7087</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.10.088</pub-id><pub-id pub-id-type="pmid">29132996</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00151"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gefenaite</surname><given-names>G.</given-names></name>
<name><surname>Munster</surname><given-names>J.M.</given-names></name>
<name><surname>van Houdt</surname><given-names>R.</given-names></name>
<name><surname>Hak</surname><given-names>E.</given-names></name>
</person-group><article-title>Effectiveness of the Q fever vaccine: A meta-analysis</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>395</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.11.008</pub-id><pub-id pub-id-type="pmid">21094268</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00151"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schoffelen</surname><given-names>T.</given-names></name>
<name><surname>Joosten</surname><given-names>L.A.B.</given-names></name>
<name><surname>Herremans</surname><given-names>T.</given-names></name>
<name><surname>de Haan</surname><given-names>A.F.J.</given-names></name>
<name><surname>Ammerdorffer</surname><given-names>A.</given-names></name>
<name><surname>R&#x000fc;mke</surname><given-names>H.C.</given-names></name>
<name><surname>Wijkmans</surname><given-names>C.J.</given-names></name>
<name><surname>Roest</surname><given-names>H.I.J.</given-names></name>
<name><surname>Netea</surname><given-names>M.G.</given-names></name>
<name><surname>van der Meer</surname><given-names>J.W.M.</given-names></name>
<etal/>
</person-group><article-title>Specific interferon &#x003b3; detection for the diagnosis of previous Q fever</article-title><source>Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.</source><year>2013</year><volume>56</volume><fpage>1742</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1093/cid/cit129</pub-id><pub-id pub-id-type="pmid">23463641</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00151"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Dow</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Sidney</surname><given-names>J.</given-names></name>
<name><surname>Read</surname><given-names>A.</given-names></name>
<name><surname>Harmsen</surname><given-names>A.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Peters</surname><given-names>B.</given-names></name>
</person-group><article-title>Identification of CD4+ T Cell Epitopes in <italic toggle="yes">C. burnetii</italic> Antigens Targeted by Antibody Responses</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e17712</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017712</pub-id><pub-id pub-id-type="pmid">21423609</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00151"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>X.</given-names></name>
<name><surname>Qi</surname><given-names>Y.</given-names></name>
<name><surname>Jiao</surname><given-names>J.</given-names></name>
<name><surname>Gong</surname><given-names>W.</given-names></name>
<name><surname>Duan</surname><given-names>C.</given-names></name>
<name><surname>Wen</surname><given-names>B.</given-names></name>
</person-group><article-title>Exploratory Study on Th1 Epitope-Induced Protective Immunity against <italic toggle="yes">Coxiella burnetii</italic> Infection</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e87206</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0087206</pub-id><pub-id pub-id-type="pmid">24498044</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00151"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Niu</surname><given-names>D.</given-names></name>
<name><surname>Wen</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Qiu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
</person-group><article-title>Protective Immunity against Q Fever Induced with a Recombinant P1 Antigen Fused with HspB of <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Ann. NY Acad. Sci.</source><year>2005</year><volume>1063</volume><fpage>130</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1196/annals.1355.021</pub-id><pub-id pub-id-type="pmid">16481504</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00151"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bach</surname><given-names>E.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>S.F.</given-names></name>
<name><surname>Williams-MacDonald</surname><given-names>S.E.</given-names></name>
<name><surname>Mitchell</surname><given-names>M.</given-names></name>
<name><surname>Golde</surname><given-names>W.T.</given-names></name>
<name><surname>Longbottom</surname><given-names>D.</given-names></name>
<name><surname>Nisbet</surname><given-names>A.J.</given-names></name>
<name><surname>Dinkla</surname><given-names>A.</given-names></name>
<name><surname>Sullivan</surname><given-names>E.</given-names></name>
<name><surname>Pinapati</surname><given-names>R.S.</given-names></name>
<etal/>
</person-group><article-title>Genome-wide epitope mapping across multiple host species reveals significant diversity in antibody responses to <italic toggle="yes">Coxiella burnetii</italic> vaccination and infection</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1257722</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1257722</pub-id><pub-id pub-id-type="pmid">37954609</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00151"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arricau-Bouvery</surname><given-names>N.</given-names></name>
<name><surname>Hauck</surname><given-names>Y.</given-names></name>
<name><surname>Bejaoui</surname><given-names>A.</given-names></name>
<name><surname>Frangoulidis</surname><given-names>D.</given-names></name>
<name><surname>Bodier</surname><given-names>C.C.</given-names></name>
<name><surname>Souriau</surname><given-names>A.</given-names></name>
<name><surname>Meyer</surname><given-names>H.</given-names></name>
<name><surname>Neubauer</surname><given-names>H.</given-names></name>
<name><surname>Rodolakis</surname><given-names>A.</given-names></name>
<name><surname>Vergnaud</surname><given-names>G.</given-names></name>
</person-group><article-title>Molecular characterization of <italic toggle="yes">Coxiella burnetii</italic> isolates by infrequent restriction site-PCR and MLVA typing</article-title><source>BMC Microbiol.</source><year>2006</year><volume>6</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-6-38</pub-id><pub-id pub-id-type="pmid">16640773</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00151"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porter</surname><given-names>S.R.</given-names></name>
<name><surname>Czaplicki</surname><given-names>G.</given-names></name>
<name><surname>Mainil</surname><given-names>J.</given-names></name>
<name><surname>Guatt&#x000e9;o</surname><given-names>R.</given-names></name>
<name><surname>Saegerman</surname><given-names>C.</given-names></name>
</person-group><article-title>Q Fever: Current state of knowledge and perspectives of research of a neglected zoonosis</article-title><source>Int. J. Microbiol.</source><year>2011</year><volume>2011</volume><elocation-id>248418</elocation-id><pub-id pub-id-type="doi">10.1155/2011/248418</pub-id><pub-id pub-id-type="pmid">22194752</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00151"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duron</surname><given-names>O.</given-names></name>
<name><surname>Doublet</surname><given-names>P.</given-names></name>
<name><surname>Vavre</surname><given-names>F.</given-names></name>
<name><surname>Bouchon</surname><given-names>D.</given-names></name>
</person-group><article-title>The Importance of Revisiting Legionellales Diversity</article-title><source>Trends Parasitol.</source><year>2018</year><volume>34</volume><fpage>1027</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2018.09.008</pub-id><pub-id pub-id-type="pmid">30322750</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00151"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>C.B.</given-names></name>
<name><surname>Evavold</surname><given-names>C.</given-names></name>
<name><surname>Kersh</surname><given-names>G.J.</given-names></name>
</person-group><article-title>The Effect of pH on Antibiotic Efficacy against <italic toggle="yes">Coxiella burnetii</italic> in Axenic Media</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>18132</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-54556-6</pub-id><pub-id pub-id-type="pmid">31792307</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00151"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vallejo Esquerra</surname><given-names>E.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Sanchez</surname><given-names>S.E.</given-names></name>
<name><surname>Omsland</surname><given-names>A.</given-names></name>
</person-group><article-title>Physicochemical and Nutritional Requirements for Axenic Replication Suggest Physiological Basis for <italic toggle="yes">Coxiella burnetii</italic> Niche Restriction</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2017</year><volume>7</volume><elocation-id>190</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2017.00190</pub-id><pub-id pub-id-type="pmid">28620582</pub-id>
</element-citation></ref><ref id="B42-vaccines-13-00151"><label>42.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>L&#x000fc;hrmann</surname><given-names>A.</given-names></name>
<name><surname>Newton</surname><given-names>H.J.</given-names></name>
<name><surname>Bonazzi</surname><given-names>M.</given-names></name>
</person-group><article-title>Beginning to Understand the Role of the Type IV Secretion System Effector Proteins in <italic toggle="yes">Coxiella burnetii</italic> Pathogenesis</article-title><source>Type IV Secretion in Gram-Negative and Gram-Positive Bacteria</source><person-group person-group-type="editor">
<name><surname>Backert</surname><given-names>S.</given-names></name>
<name><surname>Grohmann</surname><given-names>E.</given-names></name>
</person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2017</year><volume>Volume 413</volume><fpage>243</fpage><lpage>268</lpage></element-citation></ref><ref id="B43-vaccines-13-00151"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Minnick</surname><given-names>M.F.</given-names></name>
<name><surname>Raghavan</surname><given-names>R.</given-names></name>
</person-group><article-title>Developmental Biology of <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Coxiella burnetii: Recent Advances and New Perspectives in Research of the Q Fever Bacterium</source><person-group person-group-type="editor">
<name><surname>Toman</surname><given-names>R.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Mege</surname><given-names>J.L.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht, The Netherlands</publisher-loc><year>2012</year><volume>Volume 984</volume><fpage>231</fpage><lpage>248</lpage></element-citation></ref><ref id="B44-vaccines-13-00151"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>D.</given-names></name>
<name><surname>Steiner</surname><given-names>S.</given-names></name>
<name><surname>Shao</surname><given-names>M.</given-names></name>
<name><surname>Roy</surname><given-names>C.R.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
</person-group><article-title>Developmental Transitions Coordinate Assembly of the <italic toggle="yes">Coxiella burnetii</italic> Dot/Icm Type IV Secretion System</article-title><source>Infect. Immun.</source><year>2022</year><volume>90</volume><fpage>e00410</fpage><lpage>e00422</lpage><pub-id pub-id-type="doi">10.1128/iai.00410-22</pub-id><pub-id pub-id-type="pmid">36190257</pub-id>
</element-citation></ref><ref id="B45-vaccines-13-00151"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Broertjes</surname><given-names>J.</given-names></name>
<name><surname>Franz</surname><given-names>E.</given-names></name>
<name><surname>Friesema</surname><given-names>I.H.M.</given-names></name>
<name><surname>Jansen</surname><given-names>H.J.</given-names></name>
<name><surname>Reubsaet</surname><given-names>F.A.G.</given-names></name>
<name><surname>Rutjes</surname><given-names>S.A.</given-names></name>
<name><surname>Stijnis</surname><given-names>C.</given-names></name>
<name><surname>Voordouw</surname><given-names>B.C.</given-names></name>
<name><surname>de Vries</surname><given-names>M.C.</given-names></name>
<name><surname>Notermans</surname><given-names>D.W.</given-names></name>
<etal/>
</person-group><article-title>Epidemiology of Pathogens Listed as Potential Bioterrorism Agents, the Netherlands, 2009&#x02013;2019</article-title><source>Emerg Infect Dis.</source><year>2023</year><volume>29</volume><fpage>e221769</fpage><pub-id pub-id-type="doi">10.3201/eid2907.221769</pub-id><pub-id pub-id-type="pmid">37347519</pub-id>
</element-citation></ref><ref id="B46-vaccines-13-00151"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kersh</surname><given-names>G.J.</given-names></name>
<name><surname>Wolfe</surname><given-names>T.M.</given-names></name>
<name><surname>Fitzpatrick</surname><given-names>K.A.</given-names></name>
<name><surname>Candee</surname><given-names>A.J.</given-names></name>
<name><surname>Oliver</surname><given-names>L.D.</given-names></name>
<name><surname>Patterson</surname><given-names>N.E.</given-names></name>
<name><surname>Self</surname><given-names>J.S.</given-names></name>
<name><surname>Priestley</surname><given-names>R.A.</given-names></name>
<name><surname>Loftis</surname><given-names>A.D.</given-names></name>
<name><surname>Massung</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Presence of <italic toggle="yes">Coxiella burnetii</italic> DNA in the Environment of the United States, 2006 to 2008</article-title><source>Appl. Environ. Microbiol.</source><year>2010</year><volume>76</volume><fpage>4469</fpage><lpage>4475</lpage><pub-id pub-id-type="doi">10.1128/AEM.00042-10</pub-id><pub-id pub-id-type="pmid">20472727</pub-id>
</element-citation></ref><ref id="B47-vaccines-13-00151"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaplan</surname><given-names>M.M.</given-names></name>
<name><surname>Bertagna</surname><given-names>P.</given-names></name>
</person-group><article-title>The geographical distribution of Q fever</article-title><source>Bull. World Health Organ.</source><year>1955</year><volume>13</volume><fpage>829</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">13284560</pub-id>
</element-citation></ref><ref id="B48-vaccines-13-00151"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>S.A.</given-names></name>
<name><surname>Fischer</surname><given-names>E.R.</given-names></name>
<name><surname>Howe</surname><given-names>D.</given-names></name>
<name><surname>Mead</surname><given-names>D.J.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Temporal Analysis of <italic toggle="yes">Coxiella burnetii</italic> Morphological Differentiation</article-title><source>J. Bacteriol.</source><year>2004</year><volume>186</volume><fpage>7344</fpage><lpage>7352</lpage><pub-id pub-id-type="doi">10.1128/JB.186.21.7344-7352.2004</pub-id><pub-id pub-id-type="pmid">15489446</pub-id>
</element-citation></ref><ref id="B49-vaccines-13-00151"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sandoz</surname><given-names>K.M.</given-names></name>
<name><surname>Popham</surname><given-names>D.L.</given-names></name>
<name><surname>Beare</surname><given-names>P.A.</given-names></name>
<name><surname>Sturdevant</surname><given-names>D.E.</given-names></name>
<name><surname>Hansen</surname><given-names>B.</given-names></name>
<name><surname>Nair</surname><given-names>V.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Transcriptional Profiling of <italic toggle="yes">Coxiella burnetii</italic> Reveals Extensive Cell Wall Remodeling in the Small Cell Variant Developmental Form</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0149957</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0149957</pub-id><pub-id pub-id-type="pmid">26909555</pub-id>
</element-citation></ref><ref id="B50-vaccines-13-00151"><label>50.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Lightfoot</surname><given-names>N.F.</given-names></name>
<name><surname>Lloyd</surname><given-names>G.</given-names></name>
</person-group><article-title>Coxiella burnetii</article-title><source>Topley &#x00026; Wilson&#x02019;s Microbiology and Microbial Infections</source><publisher-name>John Wiley &#x00026; Sons, Ltd.</publisher-name><publisher-loc>West Sussex, UK</publisher-loc><year>2010</year><fpage>taw0081</fpage><pub-id pub-id-type="doi">10.1002/9780470688618.taw0081</pub-id></element-citation></ref><ref id="B51-vaccines-13-00151"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amano</surname><given-names>K.</given-names></name>
<name><surname>Williams</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Sensitivity of <italic toggle="yes">Coxiella burnetii</italic> peptidoglycan to lysozyme hydrolysis and correlation of sacculus rigidity with peptidoglycan-associated proteins</article-title><source>J. Bacteriol.</source><year>1984</year><volume>160</volume><fpage>989</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1128/jb.160.3.989-993.1984</pub-id><pub-id pub-id-type="pmid">6501234</pub-id>
</element-citation></ref><ref id="B52-vaccines-13-00151"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCaul</surname><given-names>T.F.</given-names></name>
<name><surname>Williams</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Developmental cycle of <italic toggle="yes">Coxiella burnetii</italic>: Structure and morphogenesis of vegetative and sporogenic differentiations</article-title><source>J. Bacteriol.</source><year>1981</year><volume>147</volume><fpage>1063</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1128/jb.147.3.1063-1076.1981</pub-id><pub-id pub-id-type="pmid">7275931</pub-id>
</element-citation></ref><ref id="B53-vaccines-13-00151"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000fc;rtler</surname><given-names>L.</given-names></name>
<name><surname>Bauerfeind</surname><given-names>U.</given-names></name>
<name><surname>Bl&#x000fc;mel</surname><given-names>J.</given-names></name>
<name><surname>Burger</surname><given-names>R.</given-names></name>
<name><surname>Drosten</surname><given-names>C.</given-names></name>
<name><surname>Gr&#x000f6;ner</surname><given-names>A.</given-names></name>
<name><surname>Heiden</surname><given-names>M.</given-names></name>
<name><surname>Hildebrandt</surname><given-names>M.</given-names></name>
<name><surname>Jansen</surname><given-names>B.</given-names></name>
<name><surname>Offergeld</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic>&#x02014;Pathogenic Agent of Q (Query) Fever</article-title><source>Transfus. Med. Hemotherapy</source><year>2014</year><volume>41</volume><fpage>60</fpage><lpage>72</lpage></element-citation></ref><ref id="B54-vaccines-13-00151"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morigen</surname><given-names>G.M.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
</person-group><article-title>Editorial: Bacterial Transcription Factors and the Cell Cycle</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><elocation-id>821394</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.821394</pub-id><pub-id pub-id-type="pmid">35003050</pub-id>
</element-citation></ref><ref id="B55-vaccines-13-00151"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sturgill-Koszycki</surname><given-names>S.</given-names></name>
<name><surname>Swanson</surname><given-names>M.S.</given-names></name>
</person-group><article-title><italic toggle="yes">Legionella pneumophila</italic> Replication Vacuoles Mature into Acidic, Endocytic Organelles</article-title><source>J. Exp. Med.</source><year>2000</year><volume>192</volume><fpage>1261</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1084/jem.192.9.1261</pub-id><pub-id pub-id-type="pmid">11067875</pub-id>
</element-citation></ref><ref id="B56-vaccines-13-00151"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hackstadt</surname><given-names>T.</given-names></name>
</person-group><article-title>The Role of Lipopolysaccharides in the Virulence of <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Ann. NY Acad. Sci.</source><year>1990</year><volume>590</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1990.tb42203.x</pub-id><pub-id pub-id-type="pmid">2378455</pub-id>
</element-citation></ref><ref id="B57-vaccines-13-00151"><label>57.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Narasaki</surname><given-names>C.T.</given-names></name>
<name><surname>Toman</surname><given-names>R.</given-names></name>
</person-group><article-title>Lipopolysaccharide of <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Coxiella burnetii: Recent Advances and New Perspectives in Research of the Q Fever Bacterium</source><person-group person-group-type="editor">
<name><surname>Toman</surname><given-names>R.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Mege</surname><given-names>J.L.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht, The Netherlands</publisher-loc><year>2012</year><volume>Volume 984</volume><fpage>65</fpage><lpage>90</lpage></element-citation></ref><ref id="B58-vaccines-13-00151"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vishwanath</surname><given-names>S.</given-names></name>
<name><surname>Hackstadt</surname><given-names>T.</given-names></name>
</person-group><article-title>Lipopolysaccharide phase variation determines the complement-mediated serum susceptibility of <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Infect. Immun.</source><year>1988</year><volume>56</volume><fpage>40</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1128/iai.56.1.40-44.1988</pub-id><pub-id pub-id-type="pmid">3335408</pub-id>
</element-citation></ref><ref id="B59-vaccines-13-00151"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zamboni</surname><given-names>D.S.</given-names></name>
<name><surname>Campos</surname><given-names>M.A.</given-names></name>
<name><surname>Torrecilhas</surname><given-names>A.C.T.</given-names></name>
<name><surname>Kiss</surname><given-names>K.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Golenbock</surname><given-names>D.T.</given-names></name>
<name><surname>Lauw</surname><given-names>F.N.</given-names></name>
<name><surname>Roy</surname><given-names>C.R.</given-names></name>
<name><surname>Almeida</surname><given-names>I.C.</given-names></name>
<name><surname>Gazzinelli</surname><given-names>R.T.</given-names></name>
</person-group><article-title>Stimulation of Toll-like Receptor 2 by <italic toggle="yes">Coxiella burnetii</italic> Is Required for Macrophage Production of Pro-inflammatory Cytokines and Resistance to Infection</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>54405</fpage><lpage>54415</lpage><pub-id pub-id-type="doi">10.1074/jbc.M410340200</pub-id><pub-id pub-id-type="pmid">15485838</pub-id>
</element-citation></ref><ref id="B60-vaccines-13-00151"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Liang</surname><given-names>X.</given-names></name>
<name><surname>Luo</surname><given-names>S.</given-names></name>
<name><surname>He</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Omsland</surname><given-names>A.</given-names></name>
<name><surname>Zhou</surname><given-names>P.</given-names></name>
<name><surname>Song</surname><given-names>L.</given-names></name>
</person-group><article-title>Lipid A Has Significance for Optimal Growth of <italic toggle="yes">Coxiella burnetii</italic> in Macrophage-Like THP-1 Cells and to a Lesser Extent in Axenic Media and Non-phagocytic Cells</article-title><source>Front. Cell Infect. Microbiol.</source><year>2018</year><volume>8</volume><elocation-id>192</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2018.00192</pub-id><pub-id pub-id-type="pmid">29938202</pub-id>
</element-citation></ref><ref id="B61-vaccines-13-00151"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varghees</surname><given-names>S.</given-names></name>
<name><surname>Kiss</surname><given-names>K.</given-names></name>
<name><surname>Frans</surname><given-names>G.</given-names></name>
<name><surname>Braha</surname><given-names>O.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Cloning and Porin Activity of the Major Outer Membrane Protein P1 from <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>6741</fpage><lpage>6750</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.12.6741-6750.2002</pub-id><pub-id pub-id-type="pmid">12438349</pub-id>
</element-citation></ref><ref id="B62-vaccines-13-00151"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sekeyov&#x000e1;</surname><given-names>Z.</given-names></name>
<name><surname>Kowalczewska</surname><given-names>M.</given-names></name>
<name><surname>Vincentelli</surname><given-names>R.</given-names></name>
<name><surname>Decloquement</surname><given-names>P.</given-names></name>
<name><surname>Flores-Ram&#x000ed;rez</surname><given-names>G.</given-names></name>
<name><surname>&#x00160;kult&#x000e9;ty</surname><given-names>&#x0013d;.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>Characterization of antigens for Q fever serodiagnostics</article-title><source>Acta Virol.</source><year>2010</year><volume>54</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.4149/av_2010_03_173</pub-id><pub-id pub-id-type="pmid">20822309</pub-id>
</element-citation></ref><ref id="B63-vaccines-13-00151"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carey</surname><given-names>K.L.</given-names></name>
<name><surname>Newton</surname><given-names>H.J.</given-names></name>
<name><surname>L&#x000fc;hrmann</surname><given-names>A.</given-names></name>
<name><surname>Roy</surname><given-names>C.R.</given-names></name>
</person-group><article-title>The <italic toggle="yes">Coxiella burnetii</italic> Dot/Icm System Delivers a Unique Repertoire of Type IV Effectors into Host Cells and Is Required for Intracellular Replication</article-title><source>PLoS Pathog.</source><year>2011</year><volume>7</volume><elocation-id>e1002056</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002056</pub-id><pub-id pub-id-type="pmid">21637816</pub-id>
</element-citation></ref><ref id="B64-vaccines-13-00151"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zusman</surname><given-names>T.</given-names></name>
<name><surname>Yerushalmi</surname><given-names>G.</given-names></name>
<name><surname>Segal</surname><given-names>G.</given-names></name>
</person-group><article-title>Functional Similarities between the icm/dot Pathogenesis Systems of <italic toggle="yes">Coxiella burnetii</italic> and <italic toggle="yes">Legionella pneumophila</italic></article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>3714</fpage><lpage>3723</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.7.3714-3723.2003</pub-id><pub-id pub-id-type="pmid">12819052</pub-id>
</element-citation></ref><ref id="B65-vaccines-13-00151"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagai</surname><given-names>H.</given-names></name>
<name><surname>Kubori</surname><given-names>T.</given-names></name>
</person-group><article-title>Type IVB Secretion Systems of Legionella and Other Gram-Negative Bacteria</article-title><source>Front. Microbiol.</source><year>2011</year><volume>2</volume><elocation-id>136</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2011.00136</pub-id><pub-id pub-id-type="pmid">21743810</pub-id>
</element-citation></ref><ref id="B66-vaccines-13-00151"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Juhas</surname><given-names>M.</given-names></name>
<name><surname>Crook</surname><given-names>D.W.</given-names></name>
<name><surname>Hood</surname><given-names>D.W.</given-names></name>
</person-group><article-title>Type IV secretion systems: Tools of bacterial horizontal gene transfer and virulence</article-title><source>Cell Microbiol.</source><year>2008</year><volume>10</volume><fpage>2377</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2008.01187.x</pub-id><pub-id pub-id-type="pmid">18549454</pub-id>
</element-citation></ref><ref id="B67-vaccines-13-00151"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Banga</surname><given-names>S.</given-names></name>
<name><surname>Mertens</surname><given-names>K.</given-names></name>
<name><surname>Weber</surname><given-names>M.M.</given-names></name>
<name><surname>Gorbaslieva</surname><given-names>I.</given-names></name>
<name><surname>Tan</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>Z.-Q.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Large-scale identification and translocation of type IV secretion substrates by <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>21755</fpage><lpage>21760</lpage><pub-id pub-id-type="doi">10.1073/pnas.1010485107</pub-id><pub-id pub-id-type="pmid">21098666</pub-id>
</element-citation></ref><ref id="B68-vaccines-13-00151"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sch&#x000e4;fer</surname><given-names>W.</given-names></name>
<name><surname>Eckart</surname><given-names>R.A.</given-names></name>
<name><surname>Schmid</surname><given-names>B.</given-names></name>
<name><surname>Cagk&#x000f6;yl&#x000fc;</surname><given-names>H.</given-names></name>
<name><surname>Hof</surname><given-names>K.</given-names></name>
<name><surname>Muller</surname><given-names>Y.A.</given-names></name>
<name><surname>L&#x000fc;hrmann</surname><given-names>A.</given-names></name>
</person-group><article-title>Nuclear trafficking of the anti-apoptotic <italic toggle="yes">Coxiella burnetii</italic> effector protein AnkG requires binding to p32 and Importin-&#x003b1;1: AnkG trafficking into the nucleus</article-title><source>Cell Microbiol.</source><year>2017</year><volume>19</volume><elocation-id>e12634</elocation-id><pub-id pub-id-type="doi">10.1111/cmi.12634</pub-id></element-citation></ref><ref id="B69-vaccines-13-00151"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eckart</surname><given-names>R.A.</given-names></name>
<name><surname>Bisle</surname><given-names>S.</given-names></name>
<name><surname>Schulze-Luehrmann</surname><given-names>J.</given-names></name>
<name><surname>Wittmann</surname><given-names>I.</given-names></name>
<name><surname>Jantsch</surname><given-names>J.</given-names></name>
<name><surname>Schmid</surname><given-names>B.</given-names></name>
<name><surname>Berens</surname><given-names>C.</given-names></name>
<name><surname>L&#x000fc;hrmann</surname><given-names>A.</given-names></name>
</person-group><article-title>Antiapoptotic Activity of <italic toggle="yes">Coxiella burnetii</italic> Effector Protein AnkG Is Controlled by p32-Dependent Trafficking</article-title><source>Infect. Immun.</source><year>2014</year><volume>82</volume><fpage>2763</fpage><lpage>2771</lpage><pub-id pub-id-type="doi">10.1128/IAI.01204-13</pub-id><pub-id pub-id-type="pmid">24733095</pub-id>
</element-citation></ref><ref id="B70-vaccines-13-00151"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Larson</surname><given-names>C.L.</given-names></name>
<name><surname>Beare</surname><given-names>P.A.</given-names></name>
<name><surname>Voth</surname><given-names>D.E.</given-names></name>
<name><surname>Howe</surname><given-names>D.</given-names></name>
<name><surname>Cockrell</surname><given-names>D.C.</given-names></name>
<name><surname>Bastidas</surname><given-names>R.J.</given-names></name>
<name><surname>Valdivia</surname><given-names>R.H.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Effector Proteins That Localize to the Parasitophorous Vacuole Membrane Promote Intracellular Replication</article-title><source>Infect. Immun.</source><year>2015</year><volume>83</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1128/IAI.02763-14</pub-id><pub-id pub-id-type="pmid">25422265</pub-id>
</element-citation></ref><ref id="B71-vaccines-13-00151"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>E.</given-names></name>
<name><surname>Allombert</surname><given-names>J.</given-names></name>
<name><surname>Cantet</surname><given-names>F.</given-names></name>
<name><surname>Lakhani</surname><given-names>A.</given-names></name>
<name><surname>Yandrapalli</surname><given-names>N.</given-names></name>
<name><surname>Neyret</surname><given-names>A.</given-names></name>
<name><surname>Norville</surname><given-names>I.H.</given-names></name>
<name><surname>Favard</surname><given-names>C.</given-names></name>
<name><surname>Muriaux</surname><given-names>D.</given-names></name>
<name><surname>Bonazzi</surname><given-names>M.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> effector CvpB modulates phosphoinositide metabolism for optimal vacuole development</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E3260</fpage><lpage>E3269</lpage><pub-id pub-id-type="doi">10.1073/pnas.1522811113</pub-id><pub-id pub-id-type="pmid">27226300</pub-id>
</element-citation></ref><ref id="B72-vaccines-13-00151"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swart</surname><given-names>A.L.</given-names></name>
<name><surname>Gomez-Valero</surname><given-names>L.</given-names></name>
<name><surname>Buchrieser</surname><given-names>C.</given-names></name>
<name><surname>Hilbi</surname><given-names>H.</given-names></name>
</person-group><article-title>Evolution and function of bacterial RCC1 repeat effectors</article-title><source>Cell Microbiol.</source><year>2020</year><volume>22</volume><elocation-id>e13246</elocation-id><pub-id pub-id-type="doi">10.1111/cmi.13246</pub-id><pub-id pub-id-type="pmid">32720355</pub-id>
</element-citation></ref><ref id="B73-vaccines-13-00151"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burette</surname><given-names>M.</given-names></name>
<name><surname>Allombert</surname><given-names>J.</given-names></name>
<name><surname>Lambou</surname><given-names>K.</given-names></name>
<name><surname>Maarifi</surname><given-names>G.</given-names></name>
<name><surname>Nisole</surname><given-names>S.</given-names></name>
<name><surname>Di Russo Case</surname><given-names>E.</given-names></name>
<name><surname>Blanchet</surname><given-names>F.P.</given-names></name>
<name><surname>Hassen-Khodja</surname><given-names>C.</given-names></name>
<name><surname>Cabantous</surname><given-names>S.</given-names></name>
<name><surname>Samuel</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Modulation of innate immune signaling by a <italic toggle="yes">Coxiella burnetii</italic> eukaryotic-like effector protein</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>13708</fpage><lpage>13718</lpage><pub-id pub-id-type="doi">10.1073/pnas.1914892117</pub-id><pub-id pub-id-type="pmid">32482853</pub-id>
</element-citation></ref><ref id="B74-vaccines-13-00151"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abou Abdallah</surname><given-names>R.</given-names></name>
<name><surname>Million</surname><given-names>M.</given-names></name>
<name><surname>Delerce</surname><given-names>J.</given-names></name>
<name><surname>Anani</surname><given-names>H.</given-names></name>
<name><surname>Diop</surname><given-names>A.</given-names></name>
<name><surname>Caputo</surname><given-names>A.</given-names></name>
<name><surname>Zgheib</surname><given-names>R.</given-names></name>
<name><surname>Rousset</surname><given-names>E.</given-names></name>
<name><surname>Boumedine</surname><given-names>K.S.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Pangenomic analysis of <italic toggle="yes">Coxiella burnetii</italic> unveils new traits in genome architecture</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>1022356</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.1022356</pub-id><pub-id pub-id-type="pmid">36478861</pub-id>
</element-citation></ref><ref id="B75-vaccines-13-00151"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beare</surname><given-names>P.A.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Howe</surname><given-names>D.</given-names></name>
<name><surname>Virtaneva</surname><given-names>K.</given-names></name>
<name><surname>Porcella</surname><given-names>S.F.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Genetic Diversity of the Q Fever Agent, <italic toggle="yes">Coxiella burnetii</italic>, Assessed by Microarray-Based Whole-Genome Comparisons</article-title><source>J. Bacteriol.</source><year>2006</year><volume>188</volume><fpage>2309</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1128/JB.188.7.2309-2324.2006</pub-id><pub-id pub-id-type="pmid">16547017</pub-id>
</element-citation></ref><ref id="B76-vaccines-13-00151"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Long</surname><given-names>C.</given-names></name>
</person-group><article-title>Q Fever Vaccine Development: Current Strategies and Future Considerations</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>1223</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10101223</pub-id><pub-id pub-id-type="pmid">34684172</pub-id>
</element-citation></ref><ref id="B77-vaccines-13-00151"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klingenbeck</surname><given-names>L.</given-names></name>
<name><surname>Eckart</surname><given-names>R.A.</given-names></name>
<name><surname>Berens</surname><given-names>C.</given-names></name>
<name><surname>L&#x000fc;hrmann</surname><given-names>A.</given-names></name>
</person-group><article-title>The <italic toggle="yes">Coxiella burnetii</italic> type IV secretion system substrate CaeB inhibits intrinsic apoptosis at the mitochondrial level: <italic toggle="yes">Coxiella burnetii</italic> anti-apoptotic effector proteins</article-title><source>Cell Microbiol.</source><year>2013</year><volume>15</volume><fpage>675</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1111/cmi.12066</pub-id><pub-id pub-id-type="pmid">23126667</pub-id>
</element-citation></ref><ref id="B78-vaccines-13-00151"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zusman</surname><given-names>T.</given-names></name>
<name><surname>Aloni</surname><given-names>G.</given-names></name>
<name><surname>Halperin</surname><given-names>E.</given-names></name>
<name><surname>Kotzer</surname><given-names>H.</given-names></name>
<name><surname>Degtyar</surname><given-names>E.</given-names></name>
<name><surname>Feldman</surname><given-names>M.</given-names></name>
<name><surname>Segal</surname><given-names>G.</given-names></name>
</person-group><article-title>The response regulator PmrA is a major regulator of the icm / dot type IV secretion system in <italic toggle="yes">Legionella pneumophila</italic> and <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Mol. Microbiol.</source><year>2007</year><volume>63</volume><fpage>1508</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2007.05604.x</pub-id><pub-id pub-id-type="pmid">17302824</pub-id>
</element-citation></ref><ref id="B79-vaccines-13-00151"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moses</surname><given-names>A.S.</given-names></name>
<name><surname>Millar</surname><given-names>J.A.</given-names></name>
<name><surname>Bonazzi</surname><given-names>M.</given-names></name>
<name><surname>Beare</surname><given-names>P.A.</given-names></name>
<name><surname>Raghavan</surname><given-names>R.</given-names></name>
</person-group><article-title>Horizontally Acquired Biosynthesis Genes Boost <italic toggle="yes">Coxiella burnetii</italic>&#x02019;s Physiology</article-title><source>Front. Cell Infect. Microbiol.</source><year>2017</year><volume>7</volume><elocation-id>174</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2017.00174</pub-id><pub-id pub-id-type="pmid">28540258</pub-id>
</element-citation></ref><ref id="B80-vaccines-13-00151"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuba</surname><given-names>M.</given-names></name>
<name><surname>Neha</surname><given-names>N.</given-names></name>
<name><surname>De Souza</surname><given-names>D.P.</given-names></name>
<name><surname>Dayalan</surname><given-names>S.</given-names></name>
<name><surname>Newson</surname><given-names>J.P.M.</given-names></name>
<name><surname>Tull</surname><given-names>D.</given-names></name>
<name><surname>McConville</surname><given-names>M.J.</given-names></name>
<name><surname>Sansom</surname><given-names>F.M.</given-names></name>
<name><surname>Newton</surname><given-names>H.J.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> utilizes both glutamate and glucose during infection with glucose uptake mediated by multiple transporters</article-title><source>Biochem. J.</source><year>2019</year><volume>476</volume><fpage>2851</fpage><lpage>2867</lpage><pub-id pub-id-type="doi">10.1042/BCJ20190504</pub-id><pub-id pub-id-type="pmid">31527117</pub-id>
</element-citation></ref><ref id="B81-vaccines-13-00151"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dragan</surname><given-names>A.L.</given-names></name>
<name><surname>Voth</surname><given-names>D.E.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic>: International pathogen of mystery</article-title><source>Microbes Infect.</source><year>2020</year><volume>22</volume><fpage>100</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2019.09.001</pub-id><pub-id pub-id-type="pmid">31574310</pub-id>
</element-citation></ref><ref id="B82-vaccines-13-00151"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samanta</surname><given-names>D.</given-names></name>
<name><surname>Clemente</surname><given-names>T.M.</given-names></name>
<name><surname>Schuler</surname><given-names>B.E.</given-names></name>
<name><surname>Gilk</surname><given-names>S.D.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Type 4B Secretion System-dependent manipulation of endolysosomal maturation is required for bacterial growth</article-title><source>PLoS Pathog.</source><year>2019</year><volume>15</volume><elocation-id>e1007855</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007855</pub-id><pub-id pub-id-type="pmid">31869379</pub-id>
</element-citation></ref><ref id="B83-vaccines-13-00151"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romano</surname><given-names>P.S.</given-names></name>
<name><surname>Gutierrez</surname><given-names>M.G.</given-names></name>
<name><surname>Ber&#x000f3;n</surname><given-names>W.</given-names></name>
<name><surname>Rabinovitch</surname><given-names>M.</given-names></name>
<name><surname>Colombo</surname><given-names>M.I.</given-names></name>
</person-group><article-title>The autophagic pathway is actively modulated by phase II <italic toggle="yes">Coxiella burnetii</italic> to efficiently replicate in the host cell</article-title><source>Cell Microbiol.</source><year>2007</year><volume>9</volume><fpage>891</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2006.00838.x</pub-id><pub-id pub-id-type="pmid">17087732</pub-id>
</element-citation></ref><ref id="B84-vaccines-13-00151"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newton</surname><given-names>H.J.</given-names></name>
<name><surname>Kohler</surname><given-names>L.J.</given-names></name>
<name><surname>McDonough</surname><given-names>J.A.</given-names></name>
<name><surname>Temoche-Diaz</surname><given-names>M.</given-names></name>
<name><surname>Crabill</surname><given-names>E.</given-names></name>
<name><surname>Hartland</surname><given-names>E.L.</given-names></name>
<name><surname>Roy</surname><given-names>C.R.</given-names></name>
</person-group><article-title>A Screen of <italic toggle="yes">Coxiella burnetii</italic> Mutants Reveals Important Roles for Dot/Icm Effectors and Host Autophagy in Vacuole Biogenesis</article-title><source>PLoS Pathog.</source><year>2014</year><volume>10</volume><elocation-id>e1004286</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004286</pub-id><pub-id pub-id-type="pmid">25080348</pub-id>
</element-citation></ref><ref id="B85-vaccines-13-00151"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kohler</surname><given-names>L.J.</given-names></name>
<name><surname>Roy</surname><given-names>C.R.</given-names></name>
</person-group><article-title>Biogenesis of the lysosome-derived vacuole containing <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Microbes Infect.</source><year>2015</year><volume>17</volume><fpage>766</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2015.08.006</pub-id><pub-id pub-id-type="pmid">26327296</pub-id>
</element-citation></ref><ref id="B86-vaccines-13-00151"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Latomanski</surname><given-names>E.A.</given-names></name>
<name><surname>Newton</surname><given-names>P.</given-names></name>
<name><surname>Khoo</surname><given-names>C.A.</given-names></name>
<name><surname>Newton</surname><given-names>H.J.</given-names></name>
</person-group><article-title>The Effector Cig57 Hijacks FCHO-Mediated Vesicular Trafficking to Facilitate Intracellular Replication of <italic toggle="yes">Coxiella burnetii</italic></article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1006101</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006101</pub-id><pub-id pub-id-type="pmid">28002452</pub-id>
</element-citation></ref><ref id="B87-vaccines-13-00151"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Winchell</surname><given-names>C.G.</given-names></name>
<name><surname>Graham</surname><given-names>J.G.</given-names></name>
<name><surname>Kurten</surname><given-names>R.C.</given-names></name>
<name><surname>Voth</surname><given-names>D.E.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Type IV Secretion-Dependent Recruitment of Macrophage Autophagosomes</article-title><source>Infect. Immun.</source><year>2014</year><volume>82</volume><fpage>2229</fpage><lpage>2238</lpage><pub-id pub-id-type="doi">10.1128/IAI.01236-13</pub-id><pub-id pub-id-type="pmid">24643534</pub-id>
</element-citation></ref><ref id="B88-vaccines-13-00151"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hardiman</surname><given-names>C.A.</given-names></name>
<name><surname>McDonough</surname><given-names>J.A.</given-names></name>
<name><surname>Newton</surname><given-names>H.J.</given-names></name>
<name><surname>Roy</surname><given-names>C.R.</given-names></name>
</person-group><article-title>The role of Rab GTPases in the transport of vacuoles containing <italic toggle="yes">Legionella pneumophila</italic> and <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Biochem. Soc. Trans.</source><year>2012</year><volume>40</volume><fpage>1353</fpage><lpage>1359</lpage><pub-id pub-id-type="doi">10.1042/BST20120167</pub-id><pub-id pub-id-type="pmid">23176480</pub-id>
</element-citation></ref><ref id="B89-vaccines-13-00151"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ber&#x000f3;n</surname><given-names>W.</given-names></name>
<name><surname>Gutierrez</surname><given-names>M.G.</given-names></name>
<name><surname>Rabinovitch</surname><given-names>M.</given-names></name>
<name><surname>Colombo</surname><given-names>M.I.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Localizes in a Rab7-Labeled Compartment with Autophagic Characteristics</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>5816</fpage><lpage>5821</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.10.5816-5821.2002</pub-id><pub-id pub-id-type="pmid">12228312</pub-id>
</element-citation></ref><ref id="B90-vaccines-13-00151"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campoy</surname><given-names>E.M.</given-names></name>
<name><surname>Zoppino</surname><given-names>F.C.M.</given-names></name>
<name><surname>Colombo</surname><given-names>M.I.</given-names></name>
</person-group><article-title>The Early Secretory Pathway Contributes to the Growth of the Coxiella -Replicative Niche</article-title><source>Infect. Immun.</source><year>2011</year><volume>79</volume><fpage>402</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1128/IAI.00688-10</pub-id><pub-id pub-id-type="pmid">20937765</pub-id>
</element-citation></ref><ref id="B91-vaccines-13-00151"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minnick</surname><given-names>M.F.</given-names></name>
<name><surname>Raghavan</surname><given-names>R.</given-names></name>
</person-group><article-title>Genetics of <italic toggle="yes">Coxiella burnetii</italic>: On the Path of Specialization</article-title><source>Future Microbiol.</source><year>2011</year><volume>6</volume><fpage>1297</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.2217/fmb.11.116</pub-id><pub-id pub-id-type="pmid">22082290</pub-id>
</element-citation></ref><ref id="B92-vaccines-13-00151"><label>92.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Mertens</surname><given-names>K.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Defense Mechanisms Against Oxidative Stress in <italic toggle="yes">Coxiella burnetii</italic>: Adaptation to a Unique Intracellular Niche</article-title><source>Coxiella burnetii: Recent Advances and New Perspectives in Research of the Q Fever Bacterium</source><person-group person-group-type="editor">
<name><surname>Toman</surname><given-names>R.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Mege</surname><given-names>J.L.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht, The Netherlands</publisher-loc><year>2012</year><volume>Volume 984</volume><fpage>39</fpage><lpage>63</lpage></element-citation></ref><ref id="B93-vaccines-13-00151"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>D.R.</given-names></name>
<name><surname>Newton</surname><given-names>P.</given-names></name>
<name><surname>Lau</surname><given-names>N.</given-names></name>
<name><surname>Newton</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Interfering with Autophagy: The Opposing Strategies Deployed by <italic toggle="yes">Legionella pneumophila</italic> and <italic toggle="yes">Coxiella burnetii</italic> Effector Proteins</article-title><source>Front. Cell Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>599762</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.599762</pub-id><pub-id pub-id-type="pmid">33251162</pub-id>
</element-citation></ref><ref id="B94-vaccines-13-00151"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Dai</surname><given-names>L.</given-names></name>
<name><surname>Ouyang</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Wen</surname><given-names>B.</given-names></name>
<name><surname>Zhou</surname><given-names>D.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Plasmid Effector B Promotes LC3-II Accumulation and Contributes To Bacterial Virulence in a SCID Mouse Model</article-title><source>Infect. Immun.</source><year>2022</year><volume>90</volume><fpage>e00016</fpage><lpage>e00022</lpage><pub-id pub-id-type="doi">10.1128/iai.00016-22</pub-id><pub-id pub-id-type="pmid">35587202</pub-id>
</element-citation></ref><ref id="B95-vaccines-13-00151"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siadous</surname><given-names>F.A.</given-names></name>
<name><surname>Cantet</surname><given-names>F.</given-names></name>
<name><surname>Van Schaik</surname><given-names>E.</given-names></name>
<name><surname>Burette</surname><given-names>M.</given-names></name>
<name><surname>Allombert</surname><given-names>J.</given-names></name>
<name><surname>Lakhani</surname><given-names>A.</given-names></name>
<name><surname>Bonaventure</surname><given-names>B.</given-names></name>
<name><surname>Goujon</surname><given-names>C.</given-names></name>
<name><surname>Samuel</surname><given-names>J.</given-names></name>
<name><surname>Bonazzi</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Coxiella effector protein CvpF subverts RAB26-dependent autophagy to promote vacuole biogenesis and virulence</article-title><source>Autophagy</source><year>2021</year><volume>17</volume><fpage>706</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1080/15548627.2020.1728098</pub-id><pub-id pub-id-type="pmid">32116095</pub-id>
</element-citation></ref><ref id="B96-vaccines-13-00151"><label>96.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Capo</surname><given-names>C.</given-names></name>
<name><surname>Mege</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Role of Innate and Adaptive Immunity in the Control of Q Fever</article-title><source>Coxiella burnetii: Recent Advances and New Perspectives in Research of the Q Fever Bacterium</source><person-group person-group-type="editor">
<name><surname>Toman</surname><given-names>R.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
<name><surname>Mege</surname><given-names>J.L.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht, The Netherlands</publisher-loc><year>2012</year><volume>Volume 984</volume><fpage>273</fpage><lpage>286</lpage></element-citation></ref><ref id="B97-vaccines-13-00151"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Honstettre</surname><given-names>A.</given-names></name>
<name><surname>Ghigo</surname><given-names>E.</given-names></name>
<name><surname>Moynault</surname><given-names>A.</given-names></name>
<name><surname>Capo</surname><given-names>C.</given-names></name>
<name><surname>Toman</surname><given-names>R.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
<name><surname>Takeuchi</surname><given-names>O.</given-names></name>
<name><surname>Lepidi</surname><given-names>H.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<name><surname>Mege</surname><given-names>J.-L.</given-names></name>
</person-group><article-title>Lipopolysaccharide from <italic toggle="yes">Coxiella burnetii</italic> Is Involved in Bacterial Phagocytosis, Filamentous Actin Reorganization, and Inflammatory Responses through Toll-Like Receptor 4</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>3695</fpage><lpage>3703</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.6.3695</pub-id><pub-id pub-id-type="pmid">15004173</pub-id>
</element-citation></ref><ref id="B98-vaccines-13-00151"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benoit</surname><given-names>M.</given-names></name>
<name><surname>Barbarat</surname><given-names>B.</given-names></name>
<name><surname>Bernard</surname><given-names>A.</given-names></name>
<name><surname>Olive</surname><given-names>D.</given-names></name>
<name><surname>Mege</surname><given-names>J.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic>, the agent of Q fever, stimulates an atypical M2 activation program in human macrophages</article-title><source>Eur. J. Immunol.</source><year>2008</year><volume>38</volume><fpage>1065</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1002/eji.200738067</pub-id><pub-id pub-id-type="pmid">18350541</pub-id>
</element-citation></ref><ref id="B99-vaccines-13-00151"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Graham</surname><given-names>J.G.</given-names></name>
<name><surname>MacDonald</surname><given-names>L.J.</given-names></name>
<name><surname>Hussain</surname><given-names>S.K.</given-names></name>
<name><surname>Sharma</surname><given-names>U.M.</given-names></name>
<name><surname>Kurten</surname><given-names>R.C.</given-names></name>
<name><surname>Voth</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Virulent <italic toggle="yes">Coxiella burnetii</italic> pathotypes productively infect primary human alveolar macrophages: Coxiella infection of alveolar macrophages</article-title><source>Cell Microbiol.</source><year>2013</year><volume>15</volume><fpage>1012</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1111/cmi.12096</pub-id><pub-id pub-id-type="pmid">23279051</pub-id>
</element-citation></ref><ref id="B100-vaccines-13-00151"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meghari</surname><given-names>S.</given-names></name>
<name><surname>Bechah</surname><given-names>Y.</given-names></name>
<name><surname>Capo</surname><given-names>C.</given-names></name>
<name><surname>Lepidi</surname><given-names>H.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<name><surname>Murray</surname><given-names>P.J.</given-names></name>
<name><surname>Mege</surname><given-names>J.-L.</given-names></name>
</person-group><article-title>Persistent <italic toggle="yes">Coxiella burnetii</italic> Infection in Mice Overexpressing IL-10: An Efficient Model for Chronic Q Fever Pathogenesis</article-title><source>PLoS Pathog</source><year>2008</year><volume>4</volume><elocation-id>e23</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0040023</pub-id><pub-id pub-id-type="pmid">18248094</pub-id>
</element-citation></ref><ref id="B101-vaccines-13-00151"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ammerdorffer</surname><given-names>A.</given-names></name>
<name><surname>Schoffelen</surname><given-names>T.</given-names></name>
<name><surname>Gresnigt</surname><given-names>M.S.</given-names></name>
<name><surname>Oosting</surname><given-names>M.</given-names></name>
<name><surname>Den Brok</surname><given-names>M.H.</given-names></name>
<name><surname>Abdollahi-Roodsaz</surname><given-names>S.</given-names></name>
<name><surname>Kanneganti</surname><given-names>T.-D.</given-names></name>
<name><surname>de Jong</surname><given-names>D.J.</given-names></name>
<name><surname>van Deuren</surname><given-names>M.</given-names></name>
<name><surname>Roest</surname><given-names>H.-J.</given-names></name>
<etal/>
</person-group><article-title>Recognition of <italic toggle="yes">Coxiella burnetii</italic> by Toll-like Receptors and Nucleotide-Binding Oligomerization Domain-like Receptors</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>211</volume><fpage>978</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu526</pub-id><pub-id pub-id-type="pmid">25246533</pub-id>
</element-citation></ref><ref id="B102-vaccines-13-00151"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andoh</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Russell-Lodrigue</surname><given-names>K.E.</given-names></name>
<name><surname>Shive</surname><given-names>H.R.</given-names></name>
<name><surname>Weeks</surname><given-names>B.R.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>T Cells Are Essential for Bacterial Clearance, and Gamma Interferon, Tumor Necrosis Factor Alpha, and B Cells Are Crucial for Disease Development in <italic toggle="yes">Coxiella burnetii</italic> Infection in Mice</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>3245</fpage><lpage>3255</lpage><pub-id pub-id-type="doi">10.1128/IAI.01767-06</pub-id><pub-id pub-id-type="pmid">17438029</pub-id>
</element-citation></ref><ref id="B103-vaccines-13-00151"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gilk</surname><given-names>S.D.</given-names></name>
<name><surname>Cockrell</surname><given-names>D.C.</given-names></name>
<name><surname>Luterbach</surname><given-names>C.</given-names></name>
<name><surname>Hansen</surname><given-names>B.</given-names></name>
<name><surname>Knodler</surname><given-names>L.A.</given-names></name>
<name><surname>Ibarra</surname><given-names>J.A.</given-names></name>
<name><surname>Steele-Mortimer</surname><given-names>O.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Bacterial Colonization of Host Cells in the Absence of Cholesterol</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003107</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003107</pub-id><pub-id pub-id-type="pmid">23358892</pub-id>
</element-citation></ref><ref id="B104-vaccines-13-00151"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Limonard</surname><given-names>G.J.M.</given-names></name>
<name><surname>Thijsen</surname><given-names>S.F.</given-names></name>
<name><surname>Bossink</surname><given-names>A.W.</given-names></name>
<name><surname>Asscheman</surname><given-names>A.</given-names></name>
<name><surname>Bouwman</surname><given-names>J.J.M.</given-names></name>
</person-group><article-title>Developing a new clinical tool for diagnosing chronic Q fever: The Coxiella ELISPOT: Table 1</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2012</year><volume>64</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2011.00890.x</pub-id><pub-id pub-id-type="pmid">22067057</pub-id>
</element-citation></ref><ref id="B105-vaccines-13-00151"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brennan</surname><given-names>R.E.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Evaluation of <italic toggle="yes">Coxiella burnetii</italic> Antibiotic Susceptibilities by Real-Time PCR Assay</article-title><source>J. Clin. Microbiol.</source><year>2003</year><volume>41</volume><fpage>1869</fpage><lpage>1874</lpage><pub-id pub-id-type="doi">10.1128/JCM.41.5.1869-1874.2003</pub-id><pub-id pub-id-type="pmid">12734219</pub-id>
</element-citation></ref><ref id="B106-vaccines-13-00151"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Read</surname><given-names>A.J.</given-names></name>
<name><surname>Erickson</surname><given-names>S.</given-names></name>
<name><surname>Harmsen</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Role of CD4+ and CD8+ T Cells in Clearance of Primary Pulmonary Infection with <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>3019</fpage><lpage>3026</lpage><pub-id pub-id-type="doi">10.1128/IAI.00101-10</pub-id><pub-id pub-id-type="pmid">20351144</pub-id>
</element-citation></ref><ref id="B107-vaccines-13-00151"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wiebe</surname><given-names>M.E.</given-names></name>
<name><surname>Burton</surname><given-names>P.R.</given-names></name>
<name><surname>Shankel</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Isolation and Characterization of Two Cell Types of Coxiella burneti Phase I</article-title><source>J. Bacteriol.</source><year>1972</year><volume>110</volume><fpage>368</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1128/jb.110.1.368-377.1972</pub-id><pub-id pub-id-type="pmid">5018025</pub-id>
</element-citation></ref><ref id="B108-vaccines-13-00151"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schramek</surname><given-names>S.</given-names></name>
<name><surname>Mayer</surname><given-names>H.</given-names></name>
</person-group><article-title>Different sugar compositions of lipopolysaccharides isolated from phase I and pure phase II cells of <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Infect. Immun.</source><year>1982</year><volume>38</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1128/iai.38.1.53-57.1982</pub-id><pub-id pub-id-type="pmid">6292100</pub-id>
</element-citation></ref><ref id="B109-vaccines-13-00151"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peacock</surname><given-names>M.G.</given-names></name>
<name><surname>Philip</surname><given-names>R.N.</given-names></name>
<name><surname>Williams</surname><given-names>J.C.</given-names></name>
<name><surname>Faulkner</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Serological evaluation of O fever in humans: Enhanced phase I titers of immunoglobulins G and A are diagnostic for Q fever endocarditis</article-title><source>Infect. Immun.</source><year>1983</year><volume>41</volume><fpage>1089</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1128/iai.41.3.1089-1098.1983</pub-id><pub-id pub-id-type="pmid">6885155</pub-id>
</element-citation></ref><ref id="B110-vaccines-13-00151"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dupont</surname><given-names>H.T.</given-names></name>
<name><surname>Thirion</surname><given-names>X.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>Q fever serology: Cutoff determination for microimmunofluorescence</article-title><source>Clin. Diagn. Lab. Immunol.</source><year>1994</year><volume>1</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1128/cdli.1.2.189-196.1994</pub-id><pub-id pub-id-type="pmid">7496944</pub-id>
</element-citation></ref><ref id="B111-vaccines-13-00151"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fournier</surname><given-names>P.E.</given-names></name>
<name><surname>Marrie</surname><given-names>T.J.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>Diagnosis of Q Fever</article-title><source>J. Clin. Microbiol.</source><year>1998</year><volume>36</volume><fpage>1823</fpage><lpage>1834</lpage><pub-id pub-id-type="doi">10.1128/JCM.36.7.1823-1834.1998</pub-id><pub-id pub-id-type="pmid">9650920</pub-id>
</element-citation></ref><ref id="B112-vaccines-13-00151"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Izzo</surname><given-names>A.A.</given-names></name>
<name><surname>Marmion</surname><given-names>B.P.</given-names></name>
</person-group><article-title>Variation in interferon-gamma responses to <italic toggle="yes">Coxiella burnetii</italic> antigens with lymphocytes from vaccinated or naturally infected subjects</article-title><source>Clin. Exp. Immunol.</source><year>2008</year><volume>94</volume><fpage>507</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.1993.tb08226.x</pub-id></element-citation></ref><ref id="B113-vaccines-13-00151"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amanna</surname><given-names>I.J.</given-names></name>
<name><surname>Slifka</surname><given-names>M.K.</given-names></name>
</person-group><article-title>Contributions of humoral and cellular immunity to vaccine-induced protection in humans</article-title><source>Virology</source><year>2011</year><volume>411</volume><fpage>206</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.12.016</pub-id><pub-id pub-id-type="pmid">21216425</pub-id>
</element-citation></ref><ref id="B114-vaccines-13-00151"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sireci</surname><given-names>G.</given-names></name>
<name><surname>Badami</surname><given-names>G.D.</given-names></name>
<name><surname>Di Liberto</surname><given-names>D.</given-names></name>
<name><surname>Blanda</surname><given-names>V.</given-names></name>
<name><surname>Grippi</surname><given-names>F.</given-names></name>
<name><surname>Di Paola</surname><given-names>L.</given-names></name>
<name><surname>Guercio</surname><given-names>A.</given-names></name>
<name><surname>de la Fuente</surname><given-names>J.</given-names></name>
<name><surname>Torina</surname><given-names>A.</given-names></name>
</person-group><article-title>Recent Advances on the Innate Immune Response to <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Front. Cell Infect. Microbiol.</source><year>2021</year><volume>11</volume><elocation-id>754455</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2021.754455</pub-id><pub-id pub-id-type="pmid">34796128</pub-id>
</element-citation></ref><ref id="B115-vaccines-13-00151"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schoffelen</surname><given-names>T.</given-names></name>
<name><surname>Textoris</surname><given-names>J.</given-names></name>
<name><surname>Bleeker-Rovers</surname><given-names>C.P.</given-names></name>
<name><surname>Ben Amara</surname><given-names>A.</given-names></name>
<name><surname>Van Der Meer</surname><given-names>J.W.M.</given-names></name>
<name><surname>Netea</surname><given-names>M.G.</given-names></name>
<name><surname>Mege</surname><given-names>J.-L.</given-names></name>
<name><surname>van Deuren</surname><given-names>M.</given-names></name>
<name><surname>van de Vosse</surname><given-names>E.</given-names></name>
</person-group><article-title>Intact interferon-&#x003b3; response against <italic toggle="yes">Coxiella burnetii</italic> by peripheral blood mononuclear cells in chronic Q fever</article-title><source>Clin. Microbiol. Infect.</source><year>2017</year><volume>23</volume><fpage>209.e9</fpage><lpage>209.e15</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.11.008</pub-id><pub-id pub-id-type="pmid">27876593</pub-id>
</element-citation></ref><ref id="B116-vaccines-13-00151"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maurin</surname><given-names>M.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>Q fever</article-title><source>Clin. Microbiol. Rev.</source><year>1999</year><volume>12</volume><fpage>518</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1128/CMR.12.4.518</pub-id><pub-id pub-id-type="pmid">10515901</pub-id>
</element-citation></ref><ref id="B117-vaccines-13-00151"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brooke</surname><given-names>R.J.</given-names></name>
<name><surname>Kretzschmar</surname><given-names>M.E.</given-names></name>
<name><surname>Mutters</surname><given-names>N.T.</given-names></name>
<name><surname>Teunis</surname><given-names>P.F.</given-names></name>
</person-group><article-title>Human dose response relation for airborne exposure to <italic toggle="yes">Coxiella burnetii</italic></article-title><source>BMC Infect. Dis.</source><year>2013</year><volume>13</volume><elocation-id>488</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2334-13-488</pub-id><pub-id pub-id-type="pmid">24138807</pub-id>
</element-citation></ref><ref id="B118-vaccines-13-00151"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sobotta</surname><given-names>K.</given-names></name>
<name><surname>Hillarius</surname><given-names>K.</given-names></name>
<name><surname>Mager</surname><given-names>M.</given-names></name>
<name><surname>Kerner</surname><given-names>K.</given-names></name>
<name><surname>Heydel</surname><given-names>C.</given-names></name>
<name><surname>Menge</surname><given-names>C.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Infects Primary Bovine Macrophages and Limits Their Host Cell Response</article-title><source>Infect. Immun.</source><year>2016</year><volume>84</volume><fpage>1722</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1128/IAI.01208-15</pub-id><pub-id pub-id-type="pmid">27021246</pub-id>
</element-citation></ref><ref id="B119-vaccines-13-00151"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<name><surname>Marrie</surname><given-names>T.</given-names></name>
<name><surname>Mege</surname><given-names>J.</given-names></name>
</person-group><article-title>Natural history and pathophysiology of Q fever</article-title><source>Lancet Infect. Dis.</source><year>2005</year><volume>5</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(05)70052-9</pub-id><pub-id pub-id-type="pmid">15792739</pub-id>
</element-citation></ref><ref id="B120-vaccines-13-00151"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Westlake</surname><given-names>P.</given-names></name>
<name><surname>Price</surname><given-names>L.M.</given-names></name>
<name><surname>Russell</surname><given-names>M.</given-names></name>
<name><surname>Kelly</surname><given-names>J.K.</given-names></name>
</person-group><article-title>The Pathology of Q Fever Hepatitis: A Case Diagnosed by Liver Biopsy</article-title><source>J. Clin. Gastroenterol.</source><year>1987</year><volume>9</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1097/00004836-198706000-00024</pub-id><pub-id pub-id-type="pmid">3611692</pub-id>
</element-citation></ref><ref id="B121-vaccines-13-00151"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schneeberger</surname><given-names>P.M.</given-names></name>
<name><surname>Wintenberger</surname><given-names>C.</given-names></name>
<name><surname>van der Hoek</surname><given-names>W.</given-names></name>
<name><surname>Stahl</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Q fever in the Netherlands&#x02014;2007&#x02013;2010: What we learned from the largest outbreak ever</article-title><source>Med. Mal. Infect.</source><year>2014</year><volume>44</volume><fpage>339</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.medmal.2014.02.006</pub-id><pub-id pub-id-type="pmid">25108615</pub-id>
</element-citation></ref><ref id="B122-vaccines-13-00151"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szablewski</surname><given-names>V.</given-names></name>
<name><surname>Costes</surname><given-names>V.</given-names></name>
<name><surname>Rousset</surname><given-names>T.</given-names></name>
<name><surname>Mania</surname><given-names>E.</given-names></name>
<name><surname>El Aoufi</surname><given-names>N.</given-names></name>
</person-group><article-title>Fi&#x000e8;vreQ: Localisationm&#x000e9;dullaire d&#x02019;un granulomecaract&#x000e9;ristique</article-title><source>Ann. Pathol.</source><year>2012</year><volume>32</volume><fpage>263</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.annpat.2012.05.003</pub-id><pub-id pub-id-type="pmid">23010400</pub-id>
</element-citation></ref><ref id="B123-vaccines-13-00151"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palmela</surname><given-names>C.</given-names></name>
<name><surname>Badura</surname><given-names>R.</given-names></name>
<name><surname>Valadas</surname><given-names>E.</given-names></name>
</person-group><article-title>cute Q fever in Portugal. Epidemiological and clinical features of 32 hospitalized patients</article-title><source>GERMS</source><year>2012</year><volume>2</volume><fpage>43</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.11599/germs.2012.1013</pub-id><pub-id pub-id-type="pmid">24432263</pub-id>
</element-citation></ref><ref id="B124-vaccines-13-00151"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melenotte</surname><given-names>C.</given-names></name>
<name><surname>Million</surname><given-names>M.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>New insights in <italic toggle="yes">Coxiella burnetii</italic> infection: Diagnosis and therapeutic update</article-title><source>Expert. Rev. Anti Infect. Ther.</source><year>2020</year><volume>18</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1080/14787210.2020.1699055</pub-id><pub-id pub-id-type="pmid">31782315</pub-id>
</element-citation></ref><ref id="B125-vaccines-13-00151"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Million</surname><given-names>M.</given-names></name>
<name><surname>Thuny</surname><given-names>F.</given-names></name>
<name><surname>Richet</surname><given-names>H.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>Long-term outcome of Q fever endocarditis: A 26-year personal survey</article-title><source>Lancet Infect. Dis.</source><year>2010</year><volume>10</volume><fpage>527</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(10)70135-3</pub-id><pub-id pub-id-type="pmid">20637694</pub-id>
</element-citation></ref><ref id="B126-vaccines-13-00151"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brouqui</surname><given-names>P.</given-names></name>
</person-group><article-title>Chronic Q Fever: Ninety-two Cases from France, Including 27 Cases Without Endocarditis</article-title><source>Arch. Intern. Med.</source><year>1993</year><volume>153</volume><fpage>642</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1001/archinte.1993.00410050074010</pub-id><pub-id pub-id-type="pmid">8439227</pub-id>
</element-citation></ref><ref id="B127-vaccines-13-00151"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lepidi</surname><given-names>H.</given-names></name>
<name><surname>Fournier</surname><given-names>P.E.</given-names></name>
<name><surname>Karcher</surname><given-names>H.</given-names></name>
<name><surname>Schneider</surname><given-names>T.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>Immunohistochemical detection of <italic toggle="yes">Coxiella burnetii</italic> in an aortic graft</article-title><source>Clin. Microbiol. Infect.</source><year>2009</year><volume>15</volume><issue>(Suppl. S2)</issue><fpage>171</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2008.02213.x</pub-id><pub-id pub-id-type="pmid">19548996</pub-id>
</element-citation></ref><ref id="B128-vaccines-13-00151"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Botelho-Nevers</surname><given-names>E.</given-names></name>
<name><surname>Fournier</surname><given-names>P.E.</given-names></name>
<name><surname>Richet</surname><given-names>H.</given-names></name>
<name><surname>Fenollar</surname><given-names>F.</given-names></name>
<name><surname>Lepidi</surname><given-names>H.</given-names></name>
<name><surname>Foucault</surname><given-names>C.</given-names></name>
<name><surname>Branchereau</surname><given-names>A.</given-names></name>
<name><surname>Piquet</surname><given-names>P.</given-names></name>
<name><surname>Maurin</surname><given-names>M.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> infection of aortic aneurysms or vascular grafts: Report of 30 new cases and evaluation of outcome</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2007</year><volume>26</volume><fpage>635</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1007/s10096-007-0357-6</pub-id><pub-id pub-id-type="pmid">17629755</pub-id>
</element-citation></ref><ref id="B129-vaccines-13-00151"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benslimani</surname><given-names>A.</given-names></name>
<name><surname>Fenollar</surname><given-names>F.</given-names></name>
<name><surname>Lepidi</surname><given-names>H.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>Bacterial Zoonoses and Infective Endocarditis, Algeria</article-title><source>Emerg. Infect. Dis.</source><year>2005</year><volume>11</volume><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.3201/eid1102.040668</pub-id><pub-id pub-id-type="pmid">15752438</pub-id>
</element-citation></ref><ref id="B130-vaccines-13-00151"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hagenaars</surname><given-names>J.C.J.P.</given-names></name>
<name><surname>Wever</surname><given-names>P.C.</given-names></name>
<name><surname>Van Petersen</surname><given-names>A.S.</given-names></name>
<name><surname>Lestrade</surname><given-names>P.J.</given-names></name>
<name><surname>De Jager-Leclercq</surname><given-names>M.G.L.</given-names></name>
<name><surname>Hermans</surname><given-names>M.H.A.</given-names></name>
<name><surname>Moll</surname><given-names>F.L.</given-names></name>
<name><surname>Koning</surname><given-names>O.H.</given-names></name>
<name><surname>Renders</surname><given-names>N.H.</given-names></name>
</person-group><article-title>Estimated prevalence of chronic Q fever among <italic toggle="yes">Coxiella burnetii</italic> seropositive patients with an abdominal aortic/iliac aneurysm or aorto-iliac reconstruction after a large Dutch Q fever outbreak</article-title><source>J. Infect.</source><year>2014</year><volume>69</volume><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2014.03.009</pub-id><pub-id pub-id-type="pmid">24647145</pub-id>
</element-citation></ref><ref id="B131-vaccines-13-00151"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghigo</surname><given-names>E.</given-names></name>
<name><surname>Pretat</surname><given-names>L.</given-names></name>
<name><surname>Desnues</surname><given-names>B.</given-names></name>
<name><surname>Capo</surname><given-names>C.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<name><surname>Mege</surname><given-names>J.</given-names></name>
</person-group><article-title>Intracellular Life of <italic toggle="yes">Coxiella burnetii</italic> in Macrophages: An Update</article-title><source>Ann. NY Acad. Sci.</source><year>2009</year><volume>1166</volume><fpage>55</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04515.x</pub-id><pub-id pub-id-type="pmid">19538264</pub-id>
</element-citation></ref><ref id="B132-vaccines-13-00151"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ka</surname><given-names>M.B.</given-names></name>
<name><surname>Mezouar</surname><given-names>S.</given-names></name>
<name><surname>Ben Amara</surname><given-names>A.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<name><surname>Ghigo</surname><given-names>E.</given-names></name>
<name><surname>Olive</surname><given-names>D.</given-names></name>
<name><surname>Mege</surname><given-names>J.-L.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Induces Inflammatory Interferon-Like Signature in Plasmacytoid Dendritic Cells: A New Feature of Immune Response in Q Fever</article-title><source>Front. Cell Infect. Microbiol.</source><year>2016</year><volume>6</volume><elocation-id>70</elocation-id><comment>Available online: <ext-link xlink:href="http://journal.frontiersin.org/Article/10.3389/fcimb.2016.00070/abstract" ext-link-type="uri">http://journal.frontiersin.org/Article/10.3389/fcimb.2016.00070/abstract</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-20">(accessed on 20 November 2024)</date-in-citation><pub-id pub-id-type="doi">10.3389/fcimb.2016.00070</pub-id><pub-id pub-id-type="pmid">27446817</pub-id>
</element-citation></ref><ref id="B133-vaccines-13-00151"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dellacasagrande</surname><given-names>J.</given-names></name>
<name><surname>Ghigo</surname><given-names>E.</given-names></name>
<name><surname>Machergui-El</surname><given-names>S.</given-names></name>
<name><surname>Hammami Toman</surname><given-names>R.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<name><surname>Capo</surname><given-names>T.</given-names></name>
<name><surname>Mege</surname><given-names>J.-L.</given-names></name>
</person-group><article-title>&#x003b1;v &#x003b2;3 Integrin and Bacterial Lipopolysaccharide Are Involved in <italic toggle="yes">Coxiella burnetii</italic> -Stimulated Production of Tumor Necrosis Factor by Human Monocytes</article-title><source>Infect. Immun.</source><year>2000</year><volume>68</volume><fpage>5673</fpage><lpage>5678</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.10.5673-5678.2000</pub-id><pub-id pub-id-type="pmid">10992470</pub-id>
</element-citation></ref><ref id="B134-vaccines-13-00151"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eldin</surname><given-names>C.</given-names></name>
<name><surname>Angelakis</surname><given-names>E.</given-names></name>
<name><surname>Renvois&#x000e9;</surname><given-names>A.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> DNA, But Not Viable Bacteria, in Dairy Products in France</article-title><source>Am. Soc. Trop. Med. Hyg.</source><year>2013</year><volume>88</volume><fpage>765</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.12-0212</pub-id><pub-id pub-id-type="pmid">23382158</pub-id>
</element-citation></ref><ref id="B135-vaccines-13-00151"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ben Amara</surname><given-names>A.</given-names></name>
<name><surname>Ghigo</surname><given-names>E.</given-names></name>
<name><surname>Le Priol</surname><given-names>Y.</given-names></name>
<name><surname>L&#x000e9;polard</surname><given-names>C.</given-names></name>
<name><surname>Salcedo</surname><given-names>S.P.</given-names></name>
<name><surname>Lemichez</surname><given-names>E.</given-names></name>
<name><surname>Bretelle</surname><given-names>F.</given-names></name>
<name><surname>Capo</surname><given-names>C.</given-names></name>
<name><surname>Mege</surname><given-names>J.-L.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic>, the Agent of Q Fever, Replicates within Trophoblasts and Induces a Unique Transcriptional Response</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e15315</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0015315</pub-id><pub-id pub-id-type="pmid">21179488</pub-id>
</element-citation></ref><ref id="B136-vaccines-13-00151"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gilot</surname><given-names>B.</given-names></name>
<name><surname>Pautou</surname><given-names>G.</given-names></name>
<name><surname>Moncada</surname><given-names>E.</given-names></name>
<name><surname>Ain</surname><given-names>G.</given-names></name>
</person-group><article-title>Ecological study of Ixodes ricinus (Linn&#x000e9;, 1758) (Acarina, Ixodoides) in southeastern France</article-title><source>Acta Trop.</source><year>1975</year><volume>32</volume><fpage>232</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">1985</pub-id>
</element-citation></ref><ref id="B137-vaccines-13-00151"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Delaby</surname><given-names>A.</given-names></name>
<name><surname>Gorvel</surname><given-names>L.</given-names></name>
<name><surname>Espinosa</surname><given-names>L.</given-names></name>
<name><surname>L&#x000e9;polard</surname><given-names>C.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<name><surname>Ghigo</surname><given-names>E.</given-names></name>
<name><surname>Capo</surname><given-names>C.</given-names></name>
<name><surname>Mege</surname><given-names>J.-L.</given-names></name>
</person-group><article-title>Defective Monocyte Dynamics in Q Fever Granuloma Deficiency</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>205</volume><fpage>1086</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis013</pub-id><pub-id pub-id-type="pmid">22351939</pub-id>
</element-citation></ref><ref id="B138-vaccines-13-00151"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Loenhout</surname><given-names>J.A.F.</given-names></name>
<name><surname>van Tiel</surname><given-names>H.H.M.M.</given-names></name>
<name><surname>van den Heuvel</surname><given-names>J.</given-names></name>
<name><surname>Vercoulen</surname><given-names>J.H.</given-names></name>
<name><surname>Bor</surname><given-names>H.</given-names></name>
<name><surname>van der Velden</surname><given-names>K.</given-names></name>
<name><surname>Paget</surname><given-names>W.J.</given-names></name>
<name><surname>Hautvast</surname><given-names>J.L.A.</given-names></name>
</person-group><article-title>Serious long-term health consequences of Q-fever and Legionnaires&#x02019; disease</article-title><source>J. Infect.</source><year>2014</year><volume>68</volume><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2014.01.004</pub-id><pub-id pub-id-type="pmid">24468188</pub-id>
</element-citation></ref><ref id="B139-vaccines-13-00151"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McQuiston</surname><given-names>J.H.</given-names></name>
<name><surname>Childs</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Q Fever in Humans and Animals in the United States</article-title><source>Vector Borne Zoonotic Dis.</source><year>2002</year><volume>2</volume><fpage>179</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1089/15303660260613747</pub-id><pub-id pub-id-type="pmid">12737547</pub-id>
</element-citation></ref><ref id="B140-vaccines-13-00151"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scholzen</surname><given-names>A.</given-names></name>
<name><surname>Richard</surname><given-names>G.</given-names></name>
<name><surname>Moise</surname><given-names>L.</given-names></name>
<name><surname>Baeten</surname><given-names>L.A.</given-names></name>
<name><surname>Reeves</surname><given-names>P.M.</given-names></name>
<name><surname>Martin</surname><given-names>W.D.</given-names></name>
<name><surname>Brauns</surname><given-names>T.A.</given-names></name>
<name><surname>Boyle</surname><given-names>C.M.</given-names></name>
<name><surname>Paul</surname><given-names>S.R.</given-names></name>
<name><surname>Bucala</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Promiscuous <italic toggle="yes">Coxiella burnetii</italic> CD4 Epitope Clusters Associated with Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever Vaccine</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>207</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00207</pub-id><pub-id pub-id-type="pmid">30828331</pub-id>
</element-citation></ref><ref id="B141-vaccines-13-00151"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waag</surname><given-names>D.M.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic>: Host and bacterial responses to infection</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>7288</fpage><lpage>7295</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.08.002</pub-id><pub-id pub-id-type="pmid">17825460</pub-id>
</element-citation></ref><ref id="B142-vaccines-13-00151"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sluder</surname><given-names>A.E.</given-names></name>
<name><surname>Raju Paul</surname><given-names>S.</given-names></name>
<name><surname>Moise</surname><given-names>L.</given-names></name>
<name><surname>Dold</surname><given-names>C.</given-names></name>
<name><surname>Richard</surname><given-names>G.</given-names></name>
<name><surname>Silva-Reyes</surname><given-names>L.</given-names></name>
<name><surname>Baeten</surname><given-names>L.A.</given-names></name>
<name><surname>Scholzen</surname><given-names>A.</given-names></name>
<name><surname>Reeves</surname><given-names>P.M.</given-names></name>
<name><surname>Pollard</surname><given-names>A.J.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of <italic toggle="yes">Coxiella burnetii</italic> Immunity</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>901372</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.901372</pub-id><pub-id pub-id-type="pmid">35651616</pub-id>
</element-citation></ref><ref id="B143-vaccines-13-00151"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gilkes</surname><given-names>A.P.</given-names></name>
<name><surname>Albin</surname><given-names>T.J.</given-names></name>
<name><surname>Manna</surname><given-names>S.</given-names></name>
<name><surname>Supnet</surname><given-names>M.</given-names></name>
<name><surname>Ruiz</surname><given-names>S.</given-names></name>
<name><surname>Tom</surname><given-names>J.</given-names></name>
<name><surname>Badten</surname><given-names>A.J.</given-names></name>
<name><surname>Jain</surname><given-names>A.</given-names></name>
<name><surname>Nakajima</surname><given-names>R.</given-names></name>
<name><surname>Felgner</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Tuning Subunit Vaccines with Novel TLR Triagonist Adjuvants to Generate Protective Immune Responses against <italic toggle="yes">Coxiella burnetii</italic></article-title><source>J. Immunol.</source><year>2020</year><volume>204</volume><fpage>611</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1900991</pub-id><pub-id pub-id-type="pmid">31871024</pub-id>
</element-citation></ref><ref id="B144-vaccines-13-00151"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gregory</surname><given-names>A.E.</given-names></name>
<name><surname>Van Schaik</surname><given-names>E.J.</given-names></name>
<name><surname>Russell-Lodrigue</surname><given-names>K.E.</given-names></name>
<name><surname>Fratzke</surname><given-names>A.P.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title><italic toggle="yes">Coxiella burnetii</italic> Intratracheal Aerosol Infection Model in Mice, Guinea Pigs, and Nonhuman Primates</article-title><source>Infect. Immun.</source><year>2019</year><volume>87</volume><fpage>e00178-19</fpage><pub-id pub-id-type="doi">10.1128/IAI.00178-19</pub-id><pub-id pub-id-type="pmid">31501249</pub-id>
</element-citation></ref><ref id="B145-vaccines-13-00151"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>M.</given-names></name>
<name><surname>Darton</surname><given-names>T.C.</given-names></name>
<name><surname>Kimmelman</surname><given-names>J.</given-names></name>
</person-group><article-title>Decision analysis approach to risk/benefit evaluation in the ethical review of controlled human infection studies</article-title><source>Bioethics</source><year>2020</year><volume>34</volume><fpage>764</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1111/bioe.12773</pub-id><pub-id pub-id-type="pmid">32588447</pub-id>
</element-citation></ref><ref id="B146-vaccines-13-00151"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Vaccines against Coxiella infection</article-title><source>Expert. Rev. Vaccines</source><year>2004</year><volume>3</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1586/14760584.3.5.577</pub-id><pub-id pub-id-type="pmid">15485337</pub-id>
</element-citation></ref><ref id="B147-vaccines-13-00151"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smadel</surname><given-names>J.E.</given-names></name>
<name><surname>Snyder</surname><given-names>M.J.</given-names></name>
<name><surname>Robbins</surname><given-names>F.C.</given-names></name>
</person-group><article-title>Vaccination against Q fever</article-title><source>Am. J. Hyg.</source><year>1948</year><volume>47</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">18921441</pub-id>
</element-citation></ref><ref id="B148-vaccines-13-00151"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bell</surname><given-names>J.F.</given-names></name>
<name><surname>Lackman</surname><given-names>D.B.</given-names></name>
<name><surname>Meis</surname><given-names>A.</given-names></name>
<name><surname>Hadlow</surname><given-names>W.J.</given-names></name>
</person-group><article-title>Recurrent Reaction of Site of Q Fever Vaccination in a Sensitized Person</article-title><source>Mil. Med.</source><year>1964</year><volume>129</volume><fpage>591</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1093/milmed/129.7.591</pub-id><pub-id pub-id-type="pmid">14199980</pub-id>
</element-citation></ref><ref id="B149-vaccines-13-00151"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaz&#x000e1;r</surname><given-names>J.</given-names></name>
<name><surname>Brezina</surname><given-names>R.</given-names></name>
<name><surname>Palanov&#x000e1;</surname><given-names>A.</given-names></name>
<name><surname>Tvrd&#x000e1;</surname><given-names>B.</given-names></name>
<name><surname>Schramek</surname><given-names>S.</given-names></name>
</person-group><article-title>Immunogenicity and reactogenicity of a Q fever chemovaccine in persons professionally exposed to Q fever in Czechoslovakia</article-title><source>Bull. World Health Organ.</source><year>1982</year><volume>60</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">6982774</pub-id>
</element-citation></ref><ref id="B150-vaccines-13-00151"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gidding</surname><given-names>H.F.</given-names></name>
<name><surname>Wallace</surname><given-names>C.</given-names></name>
<name><surname>Lawrence</surname><given-names>G.L.</given-names></name>
<name><surname>McIntyre</surname><given-names>P.B.</given-names></name>
</person-group><article-title>Australia&#x02019;s national Q fever vaccination program</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>2037</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.007</pub-id><pub-id pub-id-type="pmid">19428827</pub-id>
</element-citation></ref><ref id="B151-vaccines-13-00151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weber</surname><given-names>M.M.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Rowin</surname><given-names>K.</given-names></name>
<name><surname>Mertens</surname><given-names>K.</given-names></name>
<name><surname>Galvan</surname><given-names>G.</given-names></name>
<name><surname>Zhi</surname><given-names>H.</given-names></name>
<name><surname>Dealing</surname><given-names>C.M.</given-names></name>
<name><surname>Roman</surname><given-names>V.A.</given-names></name>
<name><surname>Banga</surname><given-names>S.</given-names></name>
<name><surname>Tan</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Identification of <italic toggle="yes">Coxiella burnetii</italic> Type IV Secretion Substrates Required for Intracellular Replication and Coxiella-Containing Vacuole Formation</article-title><source>J. Bacteriol.</source><year>2013</year><volume>195</volume><fpage>3914</fpage><lpage>3924</lpage><pub-id pub-id-type="doi">10.1128/JB.00071-13</pub-id><pub-id pub-id-type="pmid">23813730</pub-id>
</element-citation></ref><ref id="B152-vaccines-13-00151"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beare</surname><given-names>P.A.</given-names></name>
<name><surname>Gilk</surname><given-names>S.D.</given-names></name>
<name><surname>Larson</surname><given-names>C.L.</given-names></name>
<name><surname>Hill</surname><given-names>J.</given-names></name>
<name><surname>Stead</surname><given-names>C.M.</given-names></name>
<name><surname>Omsland</surname><given-names>A.</given-names></name>
<name><surname>Cockrell</surname><given-names>D.C.</given-names></name>
<name><surname>Howe</surname><given-names>D.</given-names></name>
<name><surname>Voth</surname><given-names>D.E.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Dot/Icm Type IVB Secretion System Requirements for <italic toggle="yes">Coxiella burnetii</italic> Growth in Human Macrophages</article-title><source>mBio</source><year>2011</year><volume>2</volume><fpage>e00175-11</fpage><pub-id pub-id-type="doi">10.1128/mBio.00175-11</pub-id><pub-id pub-id-type="pmid">21862628</pub-id>
</element-citation></ref><ref id="B153-vaccines-13-00151"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Schaik</surname><given-names>E.J.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Mertens</surname><given-names>K.</given-names></name>
<name><surname>Weber</surname><given-names>M.M.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Molecular pathogenesis of the obligate intracellular bacterium <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Nat. Rev. Microbiol.</source><year>2013</year><volume>11</volume><fpage>561</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3049</pub-id><pub-id pub-id-type="pmid">23797173</pub-id>
</element-citation></ref><ref id="B154-vaccines-13-00151"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roest</surname><given-names>H.I.J.</given-names></name>
<name><surname>Tilburg</surname><given-names>J.J.H.C.</given-names></name>
<name><surname>van der Hoek</surname><given-names>W.</given-names></name>
<name><surname>Vellema</surname><given-names>P.</given-names></name>
<name><surname>van Zijderveld</surname><given-names>F.G.</given-names></name>
<name><surname>Klaassen</surname><given-names>C.H.W.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>The Q fever epidemic in The Netherlands: History, onset, response and reflection</article-title><source>Epidemiol. Infect.</source><year>2011</year><volume>139</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1017/S0950268810002268</pub-id><pub-id pub-id-type="pmid">20920383</pub-id>
</element-citation></ref><ref id="B155-vaccines-13-00151"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kersh</surname><given-names>G.J.</given-names></name>
<name><surname>Fitzpatrick</surname><given-names>K.A.</given-names></name>
<name><surname>Self</surname><given-names>J.S.</given-names></name>
<name><surname>Biggerstaff</surname><given-names>B.J.</given-names></name>
<name><surname>Massung</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Long-Term Immune Responses to <italic toggle="yes">Coxiella burnetii</italic> after Vaccination</article-title><source>Clin. Vaccine Immunol.</source><year>2013</year><volume>20</volume><fpage>129</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1128/CVI.00613-12</pub-id><pub-id pub-id-type="pmid">23192629</pub-id>
</element-citation></ref><ref id="B156-vaccines-13-00151"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fontes</surname><given-names>S.D.S.</given-names></name>
<name><surname>Maia</surname><given-names>F.D.M.</given-names></name>
<name><surname>Ataides</surname><given-names>L.S.</given-names></name>
<name><surname>Conte</surname><given-names>F.P.</given-names></name>
<name><surname>Lima-Junior</surname><given-names>J.D.C.</given-names></name>
<name><surname>Rozental</surname><given-names>T.</given-names></name>
<name><surname>da Silva Assis</surname><given-names>M.R.</given-names></name>
<name><surname>J&#x000fa;nior</surname><given-names>A.A.P.</given-names></name>
<name><surname>Fernandes</surname><given-names>J.</given-names></name>
<name><surname>de Lemos</surname><given-names>E.R.S.</given-names></name>
<etal/>
</person-group><article-title>Identification of Immunogenic Linear B-Cell Epitopes in <italic toggle="yes">C. burnetii</italic> Outer Membrane Proteins Using Immunoinformatics Approaches Reveals Potential Targets of Persistent Infections</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>1250</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10101250</pub-id><pub-id pub-id-type="pmid">34684199</pub-id>
</element-citation></ref><ref id="B157-vaccines-13-00151"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fries</surname><given-names>L.F.</given-names></name>
<name><surname>Waag</surname><given-names>D.M.</given-names></name>
<name><surname>Williams</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever</article-title><source>Infect. Immun.</source><year>1993</year><volume>61</volume><fpage>1251</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1128/iai.61.4.1251-1258.1993</pub-id><pub-id pub-id-type="pmid">8454328</pub-id>
</element-citation></ref><ref id="B158-vaccines-13-00151"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Fu</surname><given-names>M.</given-names></name>
<name><surname>Dai</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>W.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Lu</surname><given-names>Z.</given-names></name>
<name><surname>Du</surname><given-names>Z.</given-names></name>
<name><surname>Zhou</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Enhanced protection against Q fever in BALB/c mice elicited by immunization of chloroform-methanol residue of <italic toggle="yes">Coxiella burnetii</italic> via intratracheal inoculation</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>6076</fpage><lpage>6084</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.08.041</pub-id><pub-id pub-id-type="pmid">31477436</pub-id>
</element-citation></ref><ref id="B159-vaccines-13-00151"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anacker</surname><given-names>R.L.</given-names></name>
<name><surname>Lackman</surname><given-names>D.B.</given-names></name>
<name><surname>Pickens</surname><given-names>E.G.</given-names></name>
<name><surname>Ribi</surname><given-names>E.</given-names></name>
</person-group><article-title>Antigenic and Skin-Reactive Properties of Fractions of <italic toggle="yes">Coxiella burnetii</italic></article-title><source>J. Immunol.</source><year>1962</year><volume>89</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.89.1.145</pub-id></element-citation></ref><ref id="B160-vaccines-13-00151"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sluder</surname><given-names>A.E.</given-names></name>
<name><surname>Poznansky</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Q fever vaccine development: Challenges and progress in balancing safety and efficacy</article-title><source>Cell Rep. Med.</source><year>2021</year><volume>2</volume><fpage>100480</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100480</pub-id><pub-id pub-id-type="pmid">35028619</pub-id>
</element-citation></ref><ref id="B161-vaccines-13-00151"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Sharma</surname><given-names>A.K.</given-names></name>
<name><surname>Singh</surname><given-names>B.</given-names></name>
<name><surname>Sharma</surname><given-names>D.</given-names></name>
</person-group><article-title>Computational studies on metabolic pathways of <italic toggle="yes">Coxiella burnetii</italic> to combat Q fever: A roadmap to vaccine development</article-title><source>Microb. Pathog.</source><year>2025</year><volume>198</volume><fpage>107136</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2024.107136</pub-id><pub-id pub-id-type="pmid">39571832</pub-id>
</element-citation></ref><ref id="B162-vaccines-13-00151"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fratzke</surname><given-names>A.P.</given-names></name>
<name><surname>van Schaik</surname><given-names>E.J.</given-names></name>
<name><surname>Samuel</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Immunogenicity and Reactogenicity in Q Fever Vaccine Development</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>886810</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.886810</pub-id><pub-id pub-id-type="pmid">35693783</pub-id>
</element-citation></ref><ref id="B163-vaccines-13-00151"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bakhteyari</surname><given-names>H.</given-names></name>
<name><surname>Jahangiri</surname><given-names>R.</given-names></name>
<name><surname>Nazifi</surname><given-names>N.</given-names></name>
<name><surname>Kakanezhadifard</surname><given-names>A.</given-names></name>
<name><surname>Soleimani</surname><given-names>Z.</given-names></name>
<name><surname>Forouharmehr</surname><given-names>A.</given-names></name>
<name><surname>Chegeni</surname><given-names>S.A.</given-names></name>
<name><surname>Jaydari</surname><given-names>A.</given-names></name>
</person-group><article-title>Cloning and Expression of Com1 and OmpH Genes of <italic toggle="yes">Coxiella burnetii</italic> in Periplasmic Compartment of Escherichia coli with Purpose of Recombinant Subunit Vaccine Production</article-title><source>Arch. Razi Inst.</source><year>2019</year><volume>74</volume><fpage>341</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.22092/ari.2018.122911.1233</pub-id><pub-id pub-id-type="pmid">31939250</pub-id>
</element-citation></ref><ref id="B164-vaccines-13-00151"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Hoeven</surname><given-names>N.</given-names></name>
<name><surname>Joshi</surname><given-names>S.W.</given-names></name>
<name><surname>Nana</surname><given-names>G.I.</given-names></name>
<name><surname>Bosco-Lauth</surname><given-names>A.</given-names></name>
<name><surname>Fox</surname><given-names>C.</given-names></name>
<name><surname>Bowen</surname><given-names>R.A.</given-names></name>
<name><surname>Clements</surname><given-names>D.E.</given-names></name>
<name><surname>Martyak</surname><given-names>T.</given-names></name>
<name><surname>Parks</surname><given-names>D.E.</given-names></name>
<name><surname>Baldwin</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0149610</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0149610</pub-id><pub-id pub-id-type="pmid">26901122</pub-id>
</element-citation></ref><ref id="B165-vaccines-13-00151"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>J.C.</given-names></name>
<name><surname>Peacock</surname><given-names>M.G.</given-names></name>
<name><surname>McCaul</surname><given-names>T.F.</given-names></name>
</person-group><article-title>Immunological and biological characterization of <italic toggle="yes">Coxiella burnetii</italic>, phases I and II, separated from host components</article-title><source>Infect. Immun.</source><year>1981</year><volume>32</volume><fpage>840</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1128/iai.32.2.840-851.1981</pub-id><pub-id pub-id-type="pmid">7251150</pub-id>
</element-citation></ref><ref id="B166-vaccines-13-00151"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Mitchell</surname><given-names>W.J.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
</person-group><article-title>Development of a Lipopolysaccharide-Targeted Peptide Mimic Vaccine against Q Fever</article-title><source>J. Immunol.</source><year>2012</year><volume>189</volume><fpage>4909</fpage><lpage>4920</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1201622</pub-id><pub-id pub-id-type="pmid">23053512</pub-id>
</element-citation></ref><ref id="B167-vaccines-13-00151"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Cong</surname><given-names>H.</given-names></name>
</person-group><article-title>Advances in the study of HLA-restricted epitope vaccines</article-title><source>Hum. Vaccines Immunother.</source><year>2013</year><volume>9</volume><fpage>2566</fpage><lpage>2577</lpage><pub-id pub-id-type="doi">10.4161/hv.26088</pub-id></element-citation></ref><ref id="B168-vaccines-13-00151"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sam</surname><given-names>G.</given-names></name>
<name><surname>Plain</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Islam</surname><given-names>A.</given-names></name>
<name><surname>Westman</surname><given-names>M.E.</given-names></name>
<name><surname>Marsh</surname><given-names>I.</given-names></name>
<name><surname>Stenos</surname><given-names>J.</given-names></name>
<name><surname>Graves</surname><given-names>S.R.</given-names></name>
<name><surname>Rehm</surname><given-names>B.H.A.</given-names></name>
</person-group><article-title>Synthetic Particulate Subunit Vaccines for the Prevention of Q Fever</article-title><source>Adv. Healthc. Mater.</source><year>2024</year><volume>13</volume><fpage>e2302351</fpage><pub-id pub-id-type="doi">10.1002/adhm.202302351</pub-id><pub-id pub-id-type="pmid">38198823</pub-id>
</element-citation></ref><ref id="B169-vaccines-13-00151"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>M.A.</given-names></name>
<name><surname>Amin</surname><given-names>A.</given-names></name>
<name><surname>Farid</surname><given-names>A.</given-names></name>
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Waris</surname><given-names>A.</given-names></name>
<name><surname>Shinwari</surname><given-names>K.</given-names></name>
<name><surname>Hussain</surname><given-names>Y.</given-names></name>
<name><surname>Alsharif</surname><given-names>K.F.</given-names></name>
<name><surname>Alzahrani</surname><given-names>K.J.</given-names></name>
<name><surname>Khan</surname><given-names>H.</given-names></name>
</person-group><article-title>Recent Advances in Genomics-Based Approaches for the Development of Intracellular Bacterial Pathogen Vaccines</article-title><source>Pharmaceutics</source><year>2022</year><volume>15</volume><elocation-id>152</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15010152</pub-id><pub-id pub-id-type="pmid">36678781</pub-id>
</element-citation></ref><ref id="B170-vaccines-13-00151"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filipi&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>Panteli&#x00107;</surname><given-names>I.</given-names></name>
<name><surname>Nikoli&#x00107;</surname><given-names>I.</given-names></name>
<name><surname>Majhen</surname><given-names>D.</given-names></name>
<name><surname>Stoji&#x00107;-Vukani&#x00107;</surname><given-names>Z.</given-names></name>
<name><surname>Savi&#x00107;</surname><given-names>S.</given-names></name>
<name><surname>Kraji&#x00161;nik</surname><given-names>D.</given-names></name>
</person-group><article-title>Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1172</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11071172</pub-id><pub-id pub-id-type="pmid">37514991</pub-id>
</element-citation></ref><ref id="B171-vaccines-13-00151"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kozak</surname><given-names>M.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
</person-group><article-title>DNA Vaccines: Their Formulations, Engineering and Delivery</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12010071</pub-id><pub-id pub-id-type="pmid">38250884</pub-id>
</element-citation></ref><ref id="B172-vaccines-13-00151"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gurunathan</surname><given-names>S.</given-names></name>
<name><surname>Klinman</surname><given-names>D.M.</given-names></name>
<name><surname>Seder</surname><given-names>R.A.</given-names></name>
</person-group><article-title>DNA Vaccines: Immunology, Application, and Optimization</article-title><source>Annu. Rev. Immunol.</source><year>2000</year><volume>18</volume><fpage>927</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.18.1.927</pub-id><pub-id pub-id-type="pmid">10837079</pub-id>
</element-citation></ref><ref id="B173-vaccines-13-00151"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Donnelly</surname><given-names>J.J.</given-names></name>
<name><surname>Ulmer</surname><given-names>J.B.</given-names></name>
<name><surname>Shiver</surname><given-names>J.W.</given-names></name>
<name><surname>Liu</surname><given-names>M.A.</given-names></name>
</person-group><article-title>DNA Vaccines</article-title><source>Annu. Rev. Immunol.</source><year>1997</year><volume>15</volume><fpage>617</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.15.1.617</pub-id><pub-id pub-id-type="pmid">9143702</pub-id>
</element-citation></ref><ref id="B174-vaccines-13-00151"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schirmbeck</surname><given-names>R.</given-names></name>
<name><surname>Reimann</surname><given-names>J.</given-names></name>
</person-group><article-title>Revealing the Potential of DNA-Based Vaccination: Lessons Learned from the Hepatitis B Virus Surface Antigen</article-title><source>Biol. Chem.</source><year>2001</year><volume>382</volume><fpage>543</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1515/BC.2001.068</pub-id><pub-id pub-id-type="pmid">11405219</pub-id>
</element-citation></ref><ref id="B175-vaccines-13-00151"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Petrovsky</surname><given-names>N.</given-names></name>
</person-group><article-title>Molecular mechanisms for enhanced DNA vaccine immunogenicity</article-title><source>Expert. Rev. Vaccines</source><year>2016</year><volume>15</volume><fpage>313</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1586/14760584.2016.1124762</pub-id><pub-id pub-id-type="pmid">26707950</pub-id>
</element-citation></ref><ref id="B176-vaccines-13-00151"><label>176.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Maruggi</surname><given-names>G.</given-names></name>
<name><surname>Ulmer</surname><given-names>J.B.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
<name><surname>Yu</surname><given-names>D.</given-names></name>
</person-group><article-title>Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action</article-title><source>mRNA Vaccines</source><person-group person-group-type="editor">
<name><surname>Yu</surname><given-names>D.</given-names></name>
<name><surname>Petsch</surname><given-names>B.</given-names></name>
</person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2021</year><volume>Volume 440</volume><fpage>31</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1007/82_2021_233</pub-id></element-citation></ref><ref id="B177-vaccines-13-00151"><label>177.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Brito</surname><given-names>L.A.</given-names></name>
<name><surname>Kommareddy</surname><given-names>S.</given-names></name>
<name><surname>Maione</surname><given-names>D.</given-names></name>
<name><surname>Uematsu</surname><given-names>Y.</given-names></name>
<name><surname>Giovani</surname><given-names>C.</given-names></name>
<name><surname>BerlandaScorza</surname><given-names>F.</given-names></name>
<name><surname>Otten</surname><given-names>G.R.</given-names></name>
<name><surname>Yu</surname><given-names>D.</given-names></name>
<name><surname>Mandl</surname><given-names>C.W.</given-names></name>
<name><surname>Mason</surname><given-names>P.W.</given-names></name>
<etal/>
</person-group><article-title>Self-Amplifying mRNA Vaccines</article-title><source>Advances in Genetics</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2015</year><fpage>179</fpage><lpage>233</lpage></element-citation></ref><ref id="B178-vaccines-13-00151"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karam</surname><given-names>M.</given-names></name>
<name><surname>Daoud</surname><given-names>G.</given-names></name>
</person-group><article-title>mRNA vaccines: Past, present, future</article-title><source>Asian J. Pharm. Sci.</source><year>2022</year><volume>17</volume><fpage>491</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2022.05.003</pub-id><pub-id pub-id-type="pmid">36105317</pub-id>
</element-citation></ref><ref id="B179-vaccines-13-00151"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ho</surname><given-names>W.</given-names></name>
<name><surname>Gao</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><article-title>Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery</article-title><source>Adv. Healthc. Mater.</source><year>2021</year><volume>10</volume><fpage>2001812</fpage><pub-id pub-id-type="doi">10.1002/adhm.202001812</pub-id><pub-id pub-id-type="pmid">33458958</pub-id>
</element-citation></ref><ref id="B180-vaccines-13-00151"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerhardt</surname><given-names>A.</given-names></name>
<name><surname>Voigt</surname><given-names>E.</given-names></name>
<name><surname>Archer</surname><given-names>M.</given-names></name>
<name><surname>Reed</surname><given-names>S.</given-names></name>
<name><surname>Larson</surname><given-names>E.</given-names></name>
<name><surname>Van Hoeven</surname><given-names>N.</given-names></name>
<name><surname>Kramer</surname><given-names>R.</given-names></name>
<name><surname>Fox</surname><given-names>C.</given-names></name>
<name><surname>Casper</surname><given-names>C.</given-names></name>
</person-group><article-title>A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2022</year><volume>25</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2022.03.009</pub-id><pub-id pub-id-type="pmid">35308783</pub-id>
</element-citation></ref><ref id="B181-vaccines-13-00151"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaydari</surname><given-names>A.</given-names></name>
<name><surname>Nazifi</surname><given-names>N.</given-names></name>
<name><surname>Forouharmehr</surname><given-names>A.</given-names></name>
</person-group><article-title>Computational design of a novel multi-epitope vaccine against <italic toggle="yes">Coxiella burnetii</italic></article-title><source>Hum. Immunol.</source><year>2020</year><volume>81</volume><fpage>596</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2020.05.010</pub-id><pub-id pub-id-type="pmid">32718721</pub-id>
</element-citation></ref><ref id="B182-vaccines-13-00151"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hussain</surname><given-names>Z.</given-names></name>
<name><surname>Hayat</surname><given-names>C.</given-names></name>
<name><surname>Shahab</surname><given-names>M.</given-names></name>
<name><surname>Sikandar</surname><given-names>R.</given-names></name>
<name><surname>Bibi</surname><given-names>H.</given-names></name>
<name><surname>Kamil</surname><given-names>A.</given-names></name>
<name><surname>Zheng</surname><given-names>G.</given-names></name>
<name><surname>Liang</surname><given-names>C.</given-names></name>
</person-group><article-title>Immunoinformatics and Reverse Vaccinology Driven Predication of a Multi-epitope Vaccine against Borrelia burgdorferi and Validation through in silico Cloning and Immune Simulation</article-title><source>Curr. Pharm. Des.</source><year>2023</year><volume>29</volume><fpage>1504</fpage><lpage>1515</lpage><pub-id pub-id-type="pmid">37073655</pub-id>
</element-citation></ref><ref id="B183-vaccines-13-00151"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toth</surname><given-names>I.</given-names></name>
<name><surname>Simerska</surname><given-names>P.</given-names></name>
<name><surname>Fujita</surname><given-names>Y.</given-names></name>
</person-group><article-title>Recent Advances in Design and Synthesis of Self-Adjuvanting Lipopeptide Vaccines</article-title><source>Int. J. Pept. Res. Ther.</source><year>2008</year><volume>14</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1007/s10989-008-9147-y</pub-id></element-citation></ref><ref id="B184-vaccines-13-00151"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andersson</surname><given-names>L.</given-names></name>
<name><surname>Blomberg</surname><given-names>L.</given-names></name>
<name><surname>Flegel</surname><given-names>M.</given-names></name>
<name><surname>Lepsa</surname><given-names>L.</given-names></name>
<name><surname>Nilsson</surname><given-names>B.</given-names></name>
<name><surname>Verlander</surname><given-names>M.</given-names></name>
</person-group><article-title>Large-scale synthesis of peptides</article-title><source>Biopolymers</source><year>2000</year><volume>55</volume><fpage>227</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1002/1097-0282(2000)55:3&#x0003c;227::AID-BIP50&#x0003e;3.0.CO;2-7</pub-id><pub-id pub-id-type="pmid">11074417</pub-id>
</element-citation></ref><ref id="B185-vaccines-13-00151"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jabarzadeh</surname><given-names>S.</given-names></name>
<name><surname>Samiminemati</surname><given-names>A.</given-names></name>
<name><surname>Zeinoddini</surname><given-names>M.</given-names></name>
</person-group><article-title>&#x0041a;o&#x0043d;&#x00441;&#x00442;&#x00440;&#x00443;&#x00438;&#x00440;o&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; in silico &#x0043d;o&#x00432;o&#x00439; &#x0043c;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00438;&#x0044d;&#x0043f;&#x00438;&#x00442;o&#x0043f;&#x0043d;o&#x00439; &#x0043a;&#x00430;&#x0043d;&#x00434;&#x00438;&#x00434;&#x00430;&#x00442;&#x0043d;o&#x00439; &#x0043f;&#x00435;&#x0043f;&#x00442;&#x00438;&#x00434;&#x0043d;o&#x00439; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x0044b; &#x0043f;&#x00440;o&#x00442;&#x00438;&#x00432; Q-&#x0043b;&#x00438;&#x00445;o&#x00440;&#x00430;&#x00434;&#x0043a;&#x00438;</article-title><source>&#x0041c;o&#x0043b;&#x00435;&#x0043a;&#x00443;&#x0043b;&#x0044f;&#x00440;&#x0043d;&#x00430;&#x0044f; &#x00431;&#x00438;o&#x0043b;o&#x00433;&#x00438;&#x0044f;</source><year>2022</year><volume>56</volume><fpage>168</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.31857/S0026898422010037</pub-id></element-citation></ref><ref id="B186-vaccines-13-00151"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sahdev</surname><given-names>P.</given-names></name>
<name><surname>Ochyl</surname><given-names>L.J.</given-names></name>
<name><surname>Moon</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Biomaterials for Nanoparticle Vaccine Delivery Systems</article-title><source>Pharm. Res.</source><year>2014</year><volume>31</volume><fpage>2563</fpage><lpage>2582</lpage><pub-id pub-id-type="doi">10.1007/s11095-014-1419-y</pub-id><pub-id pub-id-type="pmid">24848341</pub-id>
</element-citation></ref><ref id="B187-vaccines-13-00151"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jan</surname><given-names>S.</given-names></name>
<name><surname>Gregory</surname><given-names>A.</given-names></name>
<name><surname>Felgner</surname><given-names>J.</given-names></name>
<name><surname>Davies</surname><given-names>J.</given-names></name>
<name><surname>Nakajima</surname><given-names>R.</given-names></name>
<name><surname>Jasinskas</surname><given-names>A.</given-names></name>
<name><surname>Davies</surname><given-names>D.H.</given-names></name>
<name><surname>Felgner</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Assessing Immunogenicity of Vaccines and Adjuvant Combinations for Q Fever</article-title><source>J. Immunol.</source><year>2022</year><volume>208</volume><issue>(Suppl. S1)</issue><fpage>181.03</fpage><pub-id pub-id-type="doi">10.4049/jimmunol.208.Supp.181.03</pub-id><pub-id pub-id-type="pmid">34880108</pub-id>
</element-citation></ref><ref id="B188-vaccines-13-00151"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Hagan</surname><given-names>D.T.</given-names></name>
<name><surname>Valiante</surname><given-names>N.M.</given-names></name>
</person-group><article-title>Recent advances in the discovery and delivery of vaccine adjuvants</article-title><source>Nat. Rev. Drug Discov.</source><year>2003</year><volume>2</volume><fpage>727</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1038/nrd1176</pub-id><pub-id pub-id-type="pmid">12951579</pub-id>
</element-citation></ref><ref id="B189-vaccines-13-00151"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charlton Hume</surname><given-names>H.K.</given-names></name>
<name><surname>Lua</surname><given-names>L.H.L.</given-names></name>
</person-group><article-title>Platform technologies for modern vaccine manufacturing</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>4480</fpage><lpage>4485</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.069</pub-id><pub-id pub-id-type="pmid">28347504</pub-id>
</element-citation></ref><ref id="B190-vaccines-13-00151"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verdecia</surname><given-names>M.</given-names></name>
<name><surname>Kokai-Kun</surname><given-names>J.F.</given-names></name>
<name><surname>Kibbey</surname><given-names>M.</given-names></name>
<name><surname>Acharya</surname><given-names>S.</given-names></name>
<name><surname>Venema</surname><given-names>J.</given-names></name>
<name><surname>Atouf</surname><given-names>F.</given-names></name>
</person-group><article-title>COVID-19 vaccine platforms: Delivering on a promise?</article-title><source>Hum. Vaccines Immunother.</source><year>2021</year><volume>17</volume><fpage>2873</fpage><lpage>2893</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1911204</pub-id><pub-id pub-id-type="pmid">34033528</pub-id>
</element-citation></ref><ref id="B191-vaccines-13-00151"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ackland</surname><given-names>J.R.</given-names></name>
<name><surname>Worswick</surname><given-names>D.A.</given-names></name>
<name><surname>Marmion</surname><given-names>B.P.</given-names></name>
</person-group><article-title>Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990</article-title><source>Med. J. Aust.</source><year>1994</year><volume>160</volume><fpage>704</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.1994.tb125909.x</pub-id><pub-id pub-id-type="pmid">8202006</pub-id>
</element-citation></ref><ref id="B192-vaccines-13-00151"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kermode</surname><given-names>M.</given-names></name>
<name><surname>Yong</surname><given-names>K.</given-names></name>
<name><surname>Hurley</surname><given-names>S.</given-names></name>
<name><surname>Marmion</surname><given-names>B.</given-names></name>
</person-group><article-title>An economic evaluation of increased uptake in Q fever vaccination among meat and agricultural industry workers following implementation of the National Q Fever Management Program</article-title><source>Aust. N. Z. J. Public Health</source><year>2003</year><volume>27</volume><fpage>390</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1111/j.1467-842X.2003.tb00415.x</pub-id><pub-id pub-id-type="pmid">14705300</pub-id>
</element-citation></ref><ref id="B193-vaccines-13-00151"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schimmer</surname><given-names>B.</given-names></name>
<name><surname>Notermans</surname><given-names>D.W.</given-names></name>
<name><surname>Harms</surname><given-names>M.G.</given-names></name>
<name><surname>Reimerink</surname><given-names>J.H.</given-names></name>
<name><surname>Bakker</surname><given-names>J.</given-names></name>
<name><surname>Schneeberger</surname><given-names>P.</given-names></name>
<name><surname>Mollema</surname><given-names>L.</given-names></name>
<name><surname>Teunis</surname><given-names>P.</given-names></name>
<name><surname>van Pelt</surname><given-names>W.</given-names></name>
<name><surname>van Duynhoven</surname><given-names>Y.</given-names></name>
</person-group><article-title>Low seroprevalence of Q fever in The Netherlands prior to a series of large outbreaks</article-title><source>Epidemiol. Infect.</source><year>2012</year><volume>140</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1017/S0950268811000136</pub-id><pub-id pub-id-type="pmid">21324217</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00151-f001"><label>Figure 1</label><caption><p>Timeline of major milestones in Q fever research and vaccine development (1933&#x02013;2023).</p></caption><graphic xlink:href="vaccines-13-00151-g001" position="float"/></fig><fig position="float" id="vaccines-13-00151-f002"><label>Figure 2</label><caption><p>Taxonomy of <italic toggle="yes">C. burnetii</italic>. Figure was created using <uri>Biorender.com</uri>. Accessed on 29 December 2024.</p></caption><graphic xlink:href="vaccines-13-00151-g002" position="float"/></fig><fig position="float" id="vaccines-13-00151-f003"><label>Figure 3</label><caption><p>Intracellular survival and replication of Coxiella burnetii. Figure was created using <uri>Biorender.com</uri>. Accessed on 29 December 2024.</p></caption><graphic xlink:href="vaccines-13-00151-g003" position="float"/></fig><fig position="float" id="vaccines-13-00151-f004"><label>Figure 4</label><caption><p>Q fever pathogenesis in acute and chronic forms. Figure was created using <uri>Biorender.com</uri>. Accessed on 29 December 2024.</p></caption><graphic xlink:href="vaccines-13-00151-g004" position="float"/></fig><table-wrap position="float" id="vaccines-13-00151-t001"><object-id pub-id-type="pii">vaccines-13-00151-t001_Table 1</object-id><label>Table 1</label><caption><p>Q fever vaccine characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Development Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Advantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Limitations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Immune Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Safety Profile</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#F2F2F2" rowspan="1" colspan="1">Manufacturing Considerations</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Whole-Cell Vaccines (Q-VAX)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Licensed (Australia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proven efficacy (&#x0003e;95%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Requires pre-screening</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong humoral and cellular immunity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Local reactions common</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Requires BSL-3 facilities</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long-term protection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High reactogenicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80&#x02013;82% seroconversion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DTH in pre-sensitized individuals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strict quality control</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Established manufacturing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complex production</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Robust T-cell response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mandatory screening</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complex purification</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Subunit Vaccines</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Clinical Trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced reactogenicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variable protection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved safety profile</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simpler production</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Defined composition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Requires adjuvants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IgG2c-skewed antibodies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimal adverse events</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Standard facilities</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scalable production</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple doses needed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower cellular response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No pre-screening required</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Consistent quality</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA/RNA Vaccines</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Preclinical/Early Clinical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No infectious material</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delivery challenges</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Balanced immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generally safe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Standard facilities</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stable storage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited human data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong T-cell activation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No pre-screening required</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scalable process</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Precise design</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cost considerations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sustained expression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited data available</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Easier quality control</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Multi-epitope Vaccines</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Preclinical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Rational design</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complex design</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Promising safety profile</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Consistent production</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple targets</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced memory cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Requires validation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High purity required</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced reactogenicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Manufacturing complexity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple epitope targeting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No pre-screening required</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complex quality control</td></tr></tbody></table></table-wrap></floats-group></article>